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Part 1: 
Phosphorylation of IGF1R as predictive biomarker for response to therapy in colorectal 
cancer. 
Abstract( English) 
               Insulin-like growth factor-1 receptor (IGF-1R) plays a critical role in  regulating cancer cell 
proliferation, survival and metastasis in the transformed cell. Additionally,  chemo-resistance 
acquisition, a cumbersome problem in advanced colorectal cancer (ACRC) patients. The mechanism of 
resistance acquisition is found to be  attributed to  a p-IGF-1R membrane-to-nuclear internalization that 
cannot be overcome with existing IGF-1R inhibitors. In the present study,  intriguingly 48% of cases 
were positive for p-IGF-1R. p-IGF-1R positive cases had different patterns of staining: peri- nuclear 
detected  in 76%, 11%  with nuclear localization and only 13% membrane-apical staining. 
Furthermore, Tumours with positive p-IGF-1R expression, had higher MMP7 co-expression (59%) 
compared with negative cases 13%. These findings not only indicate that, IGF-1R could be used as 
biomarker, but also could allow selection of ACRC patients who can benefit from anti-IGF-1R 
treatment.   
 
Riassunto 
L’Insulin-like factor-1 di crecità recettore (IGF-1R) gioca un ruolo critico nella regolazione della 
proliferazione delle cellule tumorali, la sopravvivenza e metastasi nella cellula trasformata. Inoltre, 
l'acquisizione di chemio-resistenza, un problema ingombrante nel carcinoma colorettale avanzato 
(ACRC) pazienti di cancaro. Il meccanismo di acquisizione resistenza è risultato essere attribuito ad 
una interiorizzazione membrana-a-nucleare p-IGF-1R che non possa essere superato con inibitori IGF-
1R esistenti. Nel presente studio, intrigante 48% dei casi erano positivi per p-IGF-1R. I casi positivi p-
IGF-1R avevano diversi modelli di colorazione: peri-nucleare rilevata nel 76%, 11% con la 
localizzazione nucleare e solo il 13% membrana apicale colorati. Inoltre, Tumori con l'espressione 
positiva p-IGF-1R, ha avuto maggiore MMP7 co-espressione (59%) rispetto ai casi negativi 13%. 
Questi risultati indicano non solo che, IGF-1R potrebbe essere utilizzato come biomarker, ma potrebbe 
anche consentire la selezione dei pazienti ACRC che possono trarre beneficio dal trattamento anti-IGF-
1R. 
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Abstract 
Anti-folate drugs are widely used in cancer therapies, and folate deficiency is considered to 
contribute to tumor genesis, but still few  is known on the actual role of folates in cell survival 
and proliferation.  
We used a human pro-myelocytic cell line (HL-60) as a model to assess the effect of folinic 
acid (5FTHF) on survival and proliferation in stringent conditions (deprivation of growth 
factors or exposure to UV light). 
5FTHF has shown to increase transient proliferation in serum-free medium, and delay 
apoptosis in a dose-dependent fashion. Conversely, 5FTHF has resulted in reducing cell 
proliferation of cells cultured in medium added with growth factors. A similar phenomenon 
has been observed in PHA-activated lymphocytes, suggesting a possible effect of 5FTHF in 
increasing autocrine-driven proliferation. 5FTHF turned out to have no effect on apoptosis 
induced by growth factors deprivation or by exposure to UV-B or UV-C. 
These results suggest a role of 5FTHF in modulating cell proliferation, and this could have an 
impact in therapies that include administration at high doses. 
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Riassunto 
I farmaci “anti – folat” sono ampiamente usati nelle terapie del cancro e la carenza di “folate” 
è considerata contribuire alla genesi tumorale , ma ancora pochi sanno il ruolo effettivo di 
“folate” nella sopravvivenza e la proliferazione cellulare . 
Abbiamo utilizzato una linea cellulare pro - mieloide umano ( HL - 60) come modello per 
valutare l'effetto di acido folico ( 5FTHF ) sulla sopravvivenza e la proliferazione in 
condizioni severe ( deprivazione di fattori di crescita o di esposizione a luce UV ) . 
5FTHF ha dimostrato di aumentare la proliferazione transitoria in terreno privo di siero e 
ritardare l'apoptosi in modo dose -dipendente . Viceversa , 5FTHF ha portato a ridurre la 
proliferazione cellulare di cellule coltivate in terreno aggiunti con fattori di crescita . Un 
fenomeno simile è stato osservato nei linfociti PHA - attivati , suggerendo un possibile effetto 
di 5FTHF ascendente proliferazione autocrino - driven. 5FTHF no ha effetto sulla apoptosi 
indotta da fattori di crescita deprivazione o da esposizione a UV - B o UV - C . 
Questi risultati suggeriscono un ruolo di 5FTHF nel modulare la proliferazione cellulare e 
questo potrebbe avere un impatto nelle terapie che comprendono la somministrazione a dosi 
elevate . 
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Introduction 
1.1  General overview: 
               The insulin – like growth factor(IGF) system compose of two cognate ligands 
namely IGF-1 and IGF-2, three cell surface receptors, six IGF binding proteins and binding 
protein proteases((Baserga et al., 1997; Pollak et al., 2004). The IGF signaling axis plays a 
fundamental role in normal growth and differentiation, furthermore, badly involved in 
directing, mediating several aspects of the malignant phenotype in a different variety of human 
malignancies(Liu et al., 1993; Khandwala et al., 2000; Moschos and Mantzoros, 2002; Bohula 
et al., 2003). 
1.1.1  Ligands: 
             The ligands IGF-1 and IGF-2 are powerful growth factors that serve a pivotal function 
in differentiation and development of the organism, tissue regulation and wound healing as 
well(Heald  et al., 2006). Both IGF-1 and IGF-2 are synthesized by liver, particularly by 
extrahepatic sites encompassing both cancer cells and stromal fibroblasts(Chen et al., 2009). 
IGFs are single chain polypeptides, consisting of A-, B-, C- and D subunits having strong 
affinity binding toward IGF-1R existing in C domain. The weak binding affinities of both 
IGF-1 and IGF-2 for insulin receptor are attributed to the lack of Thr
A8
, Ile
A10
, His
B5
 and 
Tyr
B16
 contact points in the A and B domains of IR(Gauguin et al., 2008). IGF-1 as well as 
IGF-2 share a 62% identity  in amino acid sequence, with 40% identity between IGFs and pro-
insulin(Fϋrstenberger and Senn, 2002). Interestingly, the comparative concentration of IGF-1 
and IGF-2 vary in favor of IGF-2 that being five times greater than IGF-1 levels in human 
fetuses, as well as 3.5 times greater in adult serum(Bennett et al., 1983). nevertheless, Yakar et 
al.,(2005), found the expression levels of IGF-2 in human are ranged between 2 to 6 fold 
greater than those of IGF-1, moreover, IGF-2 is implicated in the progression of diverse type 
of tumours. However, the expression of IGF-2 per se is not far enough for malignant 
transformation.    
1.1.2  Insulin like growth factor binding proteins: 
              The bioactivity and bioavailability of IGFs are modulated via a family of specific 
strong affinity binding proteins IGFBP-1- IGFBP-6(Bach et al., 2005). IGFBPs range in size 
between 24 – 40 kDa consisting of three structural subunits namely, N and C terminal domains 
that are identical containing conserved internal disulfide bonds. Intriguingly, both domains are 
 2 
 
engaged in high affinity IGF binding. Paradoxically, the central linker domain, that ain’t 
conserved among the IGFBPs, is found to be mostly structurally disorganized doesn’t play a 
genuine role in IGF binding. Nevertheless, it is a common site of post-translational 
modification such as glycosylation and phosphorylation(Leon et al., 2013).  Nearly 80% of 
circulation  IGF are attached in a ternary complex including IGFBP-3 and  abundant acid 
labile subunit(ALS)( Clemmons, 1998). IGFBPs share same affinities for both IGF-1 and IGF-
2, in contrast IGFBPs-5 and 6 link IGF-2 with10 and 100 folder higher affinity than IGF-1. In 
essence IGFBP are regulated by diverse proteases(reviewed in Andersson, 2009) 
1.1.3  IGFBP proteases: 
                    The matrix metalloproteinases(MMPs) are  peptide hydrolases, active at neutral 
pH, metal ion are prerequisite for their catalytic activity. The MMPs have been well 
recognized as IGBP protease in the serum of pregnant rodents as well as in fibroblast- 
conditioned medium(Fowlkes et al., 1994; Fowlkes et al., 1994). MMPs degrade IGFBP 
releasing IGF thus increasing the bioavailability of IGFs (Miyamotoet     al., 2004). MMP-7 is 
a member of this family, zinc- dependent enzyme produced exclusively by tumor cell, and 
implicated in many types and stages of cancer. Furthermore, this enzyme promotes and 
enhances metastasis and tumor growth via different variety of mechanisms e.g. Extra cellular 
matrix ECM degradation, regulation of angiogenesis remodeling and modulation on innate 
immunity(Chambers and  Matrisian, 1997).  
  1.1.4  Insulin like growth factor receptors IGF R: 
                   The IGF receptor family contains three transmembrane receptor tyrosine kinase 
(RTK), that mediates IGF bioactivity. In essence IGF-1R gene is positioned on chromosome 
15q26 encoding  a single polypeptide of 1367 amino acids that is basically expressed in most 
cells. Not surprisingly, the IGF-1R share around 70% amino acid homology with insulin 
receptor, as well as  their genes show noticeable homology in terms of size and exon 
organization (Ullrich et al. 1986). IR has two splice variants: IR-B isoform that regulate 
glucose uptake and mainly expressed in liver, muscle and adipose tissue, compare to IR-A 
isoform that expressed by fetal tissues and some tumors, moreover, it avidly links to IGF-II 
promoting proliferation  and survival(Sciacca et al. 2002). IGF-2R is a monomeric 
transmembrane that devoid of auto signaling activity it functions as a negative regulator of 
IGF activity by sequestration, endocytosis and degradation of IGF-2(Nolan et al. 1990). IGF-
1R as well as IR are produced as single- chain pre-pro-receptors, consist of a 30 residue single 
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peptide which is cleaved co- translationally. In transit to the membrane, pro-receptors are 
glycosylated, folded and dimerised  under control of chaperone proteins prior sending to the 
Golgi apparatus. Where the receptors are processed at a tetrabasic Arg-Lys- Arg- Arg furin 
protease cleavage site generating a (130- 135 kDa) and B(90- 97 kDa)domains of the mature 
receptor(Ullrich et al. 1986). These gathered into disulphide link tetramers that contains two 
extracellular α subunits, containing710 amino acid(aa 1-710),    that has in its structure two 
homologous domains namely L1 and L2 divided by a cysteine rich domain(48%) contains 25  
or 27 cysteines in three repeating units and two β subunits containing 627 amino acid 
residues(aa 711- 1337) distributed among the extracellular domain(196 aa), the 
transmembrane domain(aa 906- 929), and intracellular region of the β subunit, which per se 
composed of a juxtamembrane domain , tyrosine kinase(TK) domain and C- terminal domain. 
The juxtamembrane domain contains NPXY motif, that may be important for receptor 
endocytosis. The catalytic domain contains the ATP binding motif(GXGXXG) that positioned 
between 976- 981, while the catalytic lysine located at position 1003, which is crucial for Mg-
ATP binding.TK domain contains three intrinsic tyrosines, located at positions 1131, 1135 and 
1136 is important for receptor autophosphorylation. The C- terminus regions roughly the last 
amino acid contains many regulatory elements fundamental for IGF-1R function((Adams et 
al., 2000; Ward and Garrett, 2004; reviewed in Girnita  et al., 2013).  
1.1.4.1 IGF-1R Internalization : 
                      Binding of IGF ligand to its respective receptor induced autophosphorylation, 
and triggering compartmentalization of ligand/receptor complexes, resulting in detachment 
and degradation of ligand in the intracellular endosome/lysosome system, additionally, 
inactivation, recycling of receptors and termination of signal transduction(Foti et al., 2004; 
Romanelli et al., 2007). Notwithstanding, receptor endocytosis may also fundamentally, 
involved in signaling especially through Ras/MAPK pathway to mitogenic endpoint(Jensen 
and De Meyts 2009). IGF-1R mediate internalization via two canonical way clathrin and 
caveolin-1(Cav-1)(Martins et al., 2011). 
1.1.4.1.1 Clathrin- mediated endocytosis: 
                  In clathrin- mediated endocytosis, when the ligands bind to its receptor, the 
receptors move within the plasma membrane, bind to adaptor protein AP2 that, recruits 
clathrin to coat the invaginating pits at the plasma membrane hence called clathrin coated 
pits(CCP). Coated pits are pinched off thanks to the large GTPase dynamin to form clathrin 
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coated vesicles(CCV), that travel from the plasma membrane, undergo uncoating, and coalesce 
to the early endosomal compartment, which act as sorting station. Next the cargo proteins 
advance towards either the late endosome or the multi-vesicular body(MVB), wherein the 
ligand is uncoupled from the receptor primarily imputed to low pH environment of MVB, and 
the receptor is recycled back to the plasma membrane. Alternatively, they can be translocated 
to the lysosome, wherein they are degraded and destroyed(French et al., 1995; Sehat, 2007; 
Doherty and McMahon, 2009; Serini et al., 2012). The expeditious elimination of receptors 
from the cell surface and subsequent delivery to the lysosome is aimed to prevent sustained 
activation from both the plasma membrane and endocytic vesicles, which may result in cell 
transformation and tumorigenesis(reviewed in Abella and Park, 2009).     
1.1.4.1.2 Caveolin-dependent endocytosis: 
                  Caveolae are  subfamily of lipid rafts, that is exist in cell surface invaginations. It is 
well distinguished by its flask shaped morphology(Simons and Toomre, 2000). Caveolin-
1(Cav-1) is the basic protein, that form the caveolae(Salani et al., 2010). Furthermore, 
Caveolar structure and function in signaling and internalization as well depend primarily on 
Caveolin-1 and cholesterol.Cav-1 function to bind and assemble cholesterol.  The N- and C- 
termini of the caveolae are protruded into the cytoplasm, indicating that they form hairpin 
shape in the membrane beside their ability to oligmerize, additionally, Caveolin serve as a coat 
protein(Mukherjee et al., 2006; de Laurentiis et al., 2007). Moreover, Cav-1 may interplay and 
modulate the bioactivity of various proteins t through scaffolding domain implicating it as a 
regulator of signal transduction(Li et al., 1996; Couet et al., 19997; Razani et al., 2002).   
                  There is a compelling evidence indicating that, the number of caveolae in cell and 
the level of Caveolin expression are closely related to the amount of cholesterol. The higher 
amount of free cholesterol in fibroblast, the higher external concentration of low density 
lipoprotein(LDL) that, resulted in an upregulation of Caveolin mRNA and increased the 
number of caveola(Fielding et al., 1997). Maggi et al., (2002), described  the IGF-1R 
colocalization with Cav-1 in the lipid rafts enriched fraction on plasma membrane and IGF-1 
triggering phosphorylation at the level of tyrosine 14 which subsequently results in the 
translocation of Cav-1, indicating that IGF-1 could regulate its intracellular signaling 
pathways by redistribution of Cav-1 on the cell surface,  Interestingly one study showed that, 
tyrosine 14 is the principle substrate of Src kinase(Lee et al., 2000). 
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1.1.4.2 Signaling via IGF-1R: 
                       The IGF-!R is triggered by IGFs exist in the extracellular milieu, stemmed from 
paracrine, endocrine or autocrine sources. Activation of IGF-1R results in autophosphorylation 
on tyrosines 1131, 1135 and 1136 in the kinase subunit ensued by phosphorylation of 
juxtamembrane tyrosines and carboxy- terminal serines. This is followed by recruitment of 
specific- docking intermediates e.g. (IRS-1), Shc and 14-3-3 proteins(Baserga et al. 1997; 
Pollak et al. 2004). Furthermore, in the wake of stimulation with cognate IGFs, the SH2- 
containing adaptor protein Shc is mobilized to phosphorylated tyrosine residue(Tyr950) in the 
juxtamembrane region of the IGF-1R, and transduce differentiation signals via the Grb2, Ras, 
Raf and MAPK pathway(Reiss et al., 2000; Valentinis et al., 2000). IGF-1R protects cancer 
cells against apoptosis, mainly via the phosphoinositide 3-kinase (PI3K) pathway, as once 
IRS-1 is phosphorylated by the activated IGF-1R, PI3K is activated by linking to IRS-1 
through its regulatory subunit(Baserga et al., 1997). This interaction results in  the levels of 
phosphatidylinositol 3,4,5- triphosphate (PIP3), to increase, and subsequently leads to 
mobilization and activation of phosphoinositide-dependent kinase- along with AKT/protein 
kinase B. Activation of AKT causes expression of anti-apoptotic proteins, namely Bcl-2, Bcl-x 
and NF-kB (Brazil et al. 2004). Additionally, IGF mediates the activation of extracellular- 
regulated kinases(ERKs), p38 and MAPK through 14-3-3- dependent mitochondrial 
compartmentalization of RAF(Peruzzi et al. 1999).  
                 IGF-1R over expression is notoriously associated with increased predilection for 
invasion and metastasis that, mediated by myriad signaling  intermediates influencing invasive 
capacity. Not surprisingly, IGF- instigated phosphorylation of IRS-1 can impact the interaction 
between E-cadherin and b-catenin, promoting and enhancing β- catenin  transcriptional 
activity and disassociating E-cadherin from the actin cytoskeleton (Playford et al. 2000)        
                The IGF-1R is found to be overexpressed in tumors, such as colon cancer, 
melanoma, pancreas, prostate and kidney((Hellawell et al., 2002;  reviewed in Bohula et al. 
2003a).  
1.1.4.3 SUMOylation: 
                   Is a post translational modification whereby protein function is regulated. It 
involves covalent binding of ubiquitin(Ub) and ubiquitin- like(Ubl) modifiers to target 
proteins, it forms a crucial step in cellular process such as differentiation, apoptosis, cell cycle 
and stress response(reviewed in Tozluog et al., 2010). SUMO-1(Small ubiquitin like 
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modifier), is a one member of  the Ubl superfamily that linked to its target proteins and exist in 
mammal with different names(reviewed in Tozluog et al., 2010). Sehat et al., (2010), reported 
accumulation of IGF1R in the nucleus after undergoing SUMOylation. Intriguingly, nuclear 
IGF-R(nIGF-1R) was demonstrated to attach to putative enhancer site within the genomic 
DNA increasing the transcription. Interestingly, SUMOylation took place at three 
evolutionarily conservative lysine residues(K1025, K1100 and K1120) of the β domain of the 
receptor, accordingly, when these lysines were mutated the IGF-1R nuclear translocation and 
transcription activation were failed to materialize(Sehat et al., 2010).  
                 The SUMOylation cascade is  initiated by activating immature SUMO protein 
which cleaved by protease enzyme, and resulting in exposing C- terminal diglycine motif that 
is necessary for optimal adenylation by a heterodimeric SUMO E1 enzyme(also known as 
Aous1/Uba2), and hence get activated. Next SUMO activated  by SUMO activating enzyme 
SAE-1 or E1, through attacking adenylate via a conserved Cys within E1 enzyme forming an 
E1- SUMO thioester. Then activated SUMO is subsequently transferred to specific 
conjugation SUMO F2(also known as Ubc9) enzyme, that consequently establishing  E2-
SUMO thioester. Two alternative pathways can take place as final step, either E2 can straight 
away transfer SUMO to lysine residue in targeted substrate, or SUMO ligase E3( also known 
as RanBP2), may join the complex, increasing the E2  catalytic activity, and transferring 
SUMO to its targeted substrates(reviewed in Sehat et al., 2010; Tozluogˇ lu et al., 2010; 
Gareau and Lima, 2010)    
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Figure 1.1 shows the structure of IGF- 1R reproduced from (Girnita, L et al., 2013) 
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Figure 1.2 shows  the Sumoylation mechanism by E1-E2 and E1-E2-E3 enzymes. (A) 
Produced as an inactive precursor, the SUMO protein is enzymes. (A) Produced as an inactive 
precursor, the SUMO protein is cleaved, exposing its Gly-Gly motif, and gets activated. (B) 
Active SUMO is transferred by E1 enzyme Aous1/Uba2 heterodimer to the E2 enzyme Ubc9. 
(C) Two alternative pathways can follow as the third step. Ubc9 can directly transfer SUMO 
to specific targets (top). Alternatively RanBP2, an E3 enzyme, can also join the complex, 
increasing the Ubc9( reproduced from Tozluogˇ lu M et al., 2010).    
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1.1.5  Oxaliplatin: 
                Oxaliplatin(trans-L-1,2 diaminocyclohexane oxalatoplatinum), is a platinum 
complex in which diaminocyclohexane(DACH) is the carrier ligand(Pelley, 2001). oxaliplatin 
is a third generation platinum compound, and is the first efficacious platinum- based 
compound used to treat colorectal cancer(Meyerhardt and Mayer, 2005). Oxaliplatin exerts its 
cytotoxic effect via effectual  damaging and inhibiting DNA synthesis probably by forming 
adducts, commonly the intrastrand linkage of two adjacent guanines by N7 that are too 
difficult to repair(Schmidt and Chaney, 1993; reviewed in Desoize and Madoulet, 2002 ).  
oxaliplatin has synergistic effects when in a cocktail containing 5-fluorouracil and leucovorin 
(FOLFOX) for treating advanced colorectal cancer, with response rates >50% and median 
survival approaching 2 years(Alberts et al., 2005; Cassidy et al., 2004). However, resistance to 
chemotherapy is the lingering problem that encounter effective treatment of cancer, since 
sizeable of colorectal cancer patients developed resistance against oxaliplatin. Oxaliplatin- 
resistant cells are distinguished by low cellular oxaliplatin, accumulation and reduced DNA 
adducts, additionally, elevation of intracellular glutathione,  mediated by gamma-glutamyl 
transpeptidase  and altered in apoptotic pathway namely mitochondrial-mediated 
apoptosis(Mishima et al., 2002; Gourdier et al., 2002). 
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2- Objective 
Relationship between the expression and cellular localization of IGF-1R and resistance to 
chemotherapy. 
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3- Material and Methods: 
3.1 Antibody production: 
                    the peptides were prepared by solid-phase synthesis using Fmoc strategy on a 
430A peptide synthesizer (Applied Biosystems, Foster City, CA) and a 9050 Pepsynthesizer 
Plus (Perseptive Biosystems, Cambridge, MA). A 4-fold excess of Na-Fmoc amino acid, O-
benzotriazol-1-yl- N,N,N9,N9-tetramethyluronium hexafluorophosphate, and 1-
hydroxybenzotriazole and a 10-fold excess of diisopropylethylamine were used in every 
coupling reaction step. Elimination of the NH2- terminal Fmoc group was accomplished by 
20% piperidine in N,Ndimethylformamide The cleavage of peptides from the resin was carried 
out with reagent K for 2 h at room temperature with gentle stirring. Crude peptides were 
precipitated in ice-cold methyl-t- butyl ether, centrifuged, and lyophilized. Crude peptides 
were then purified by preparative reverse-phase HPLC using a Dynamax-300Å C18 column 
(25 cm 3 21.4 mm, inner diameter) with a flow rate of 9 ml/min and two solvent systems of 
0.1% trifluoroacetic acid/H2O and 0.1% trifluoroacetic acid/acetonitrile. The fractions 
containing the appropriate peptide were pooled together and lyophilized. The purity of the 
final products was assessed by analytical reverse-phase HPLC, capillary electrophoresis, and 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Pep922 was a 19-
amino-acid peptide corresponding to the C-terminus residues 1319–1337 of the human IGF-IR 
(numbering of Ullrich et al., 1986). Pep1046 was a 28-amino-acid peptide corresponding to 
residues 1310-1337 of the human IGF-IR, including a phosphotyrosyl residue at position 
1316. Its sequence is NH2-FDERQPpYAHMNGGRKNERALPLPQSSTC-COOH (Rubini et 
al., 1999). 
3.2 Immunization protocol and antibodies: 
               Peptides were dissolved in 0.1 M sodium phosphate buffer (pH 7.0) and coupled to 
activated keyhole limped hemocyanin (Pierce) by glutaradehyde. Immunogens were diluted 
1:1 with complete (first shot) or incomplete (subsequent shots) Freund’s adjuvant and injected 
intradermally in rabbits at 4-week intervals. The anti-peptide serum antibody level was 
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monitored by ELISA. To get rid of unwanted anti-C terminus antibodies, anti-pep1046 serum 
was cleared by reverse immunoaffinity purification using pep922-bound Sepharose. The 
antibody against pep1046 is hereafter referred to as anti-pY1316(Rubini et al., 1999). 
 
 
 
 
Figure 3.1  shows the sequence of antibody production 
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4- Results: 
              A study conducted in collaboration with  Codony-Servat and Maurel et al  to detect 
the localization of p-IGF-1R and resistance to oxaliplatin using our antibody(anti-pY1316). 
4.1 Chronic oxaliplatin exposure leads to acquired drug resistance  
                To investigate if chronic OXL treatment could result in acquiring drug resistance, a 
panel of two colorectal cancer cell lines (LoVo and HT-29) were chronically treated with 
increasing concentrations of OXL. Sensitivity of the basal LoVo cell line was 10-fold that of 
LoVOXAR3, 29-fold that of HT-29, and 120-fold that of HTOXAR3 (Fig 4.1). To analyze the 
OXL-induced apoptosis at 24 hours, Fas expression and caspase 8 cleavage (extrinsic 
pathway) were induced by OXL in LoVo (0.2 µM) and LoVOXAR3 (20 µM). No changes in 
these proteins were observed in HT-29 and HTOXAR3. Bcl-2 decreased in LoVo cells with 2 
µM of OXL and in LoVOXAR3 with 20 µM of OXL. Bax increased with 0.2 mM of OXL, 
but 20 mM of OXL was needed to increase Bax in LoVOXAR3. Bax increased in HT-29 (2 
µM) but was not induced in HTOXAR3 despite high 50µM doses. Bcl-2 decreased in HT-29 
at doses of 2 mM, while 20mM doses were needed for HTOXAR3 cells (Figure 4.1 A). These 
results show that the oxaliplatin-resistant cell lines exhibit more resistance to apoptosis 
induced by oxaliplatin than parental cell lines. The extrinsic pathway is only implicated in the 
LoVo cell model. 
           To further characterize the properties of LoVo and HT-29, they investigated the effects 
of chronic OXL exposure in the IGF-1R pathway. they observed an increased expression of 
caveolin-1 in LoVOXAR3 and HTOXA3R cell lines compared with the parental ones. A 
specific difference between HT-29 and HTOXAR3 was increased expression and activation of 
IGF-1R in the latter (Figure 4.1B). LoVo cell lines express very low levels of MMP-7. HT-29 
expressed MMP-7 but at a lower level than HTOXAR3. they found high levels of IGFBP-3 in 
LoVo and lower but still detectable levels in LoVOXAR3 cells. IGFBP-3 was not detected in 
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HT-29 cell lines. IGFBP-2 was also highly expressed in LoVo and was detected, with 
significantly lower expression, in LoVOXAR3 and HT-29, but not in HTOXAR3 cell line 
(Figure 4.1C). 
 
 
 
 
  
Figure 4.1 colorectal cancer cell line (LoVO and HT-29), chronically treated with oxaliplatin 
had developed drug resistance 
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 Figure 4.1 Colorectal cancer cell lines (LoVo and HT-29) chronically treated with oxaliplatin 
develop drug resistance.  
A) Apoptosis induction after oxaliplatin inhibition at different doses (0.2, 2, 20 and 50) of 
parental and chronically treated cell lines was assessed. 
B and C) Levels of IGF-1R, p-IGF-1R, MMP7, IGFBP-2 and caveolin-1 expression were 
determined by Western-blot in parental and resistant cell lines 
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D1-D4)  p-IGF-1R, MMP7 and IGFBP-3 expression was determined in cell lines by 
ELISA 
 
 
4.2 Activation of IGF-1R/PI3K-AKT pathway in cells chronically treated with OXL is 
due to increased MMP-7 and IGFBP degradation: 
                       OXL caused an increase of MMP-7 in LoVOXAR3, HT-29 and HTOXAR3 
(Figure 4.2A). In the parental HT-29, a marked decrease of IGFBP-2 expression was seen 
at 24hours (h)after 20 µM OXL exposure. Expression of IGFBP-2 was not detected in 
HTOXAR3. p-IRS-1 and p-AKT were inhibited in HT-29 at 20 μM concentration after 5’ 
of treatment and remained inhibited until 60’. This effect was not observed in the 
HTOXAR3 cell line (Figure 4.2B). They  evaluated changes at 24h of p-MAPK and p-
AKT after exposure to increasing OXL concentration (0.2, 2, 20 and 50 µmol/L). Phospho-
AKT and p-MAPK were inhibited in Lovo cell lines after OXL treatment at doses as low 
as 0.2 µM at 24 hours. This effect was not observed in HT-29 and HTOXAR3 despite the 
administration of high (50 mM) doses of OXL (Figure 2C). Interestingly, a clear decrease 
in p-AKT was noted in HT-29 but not in HTOXAR3 at 1 hour after OXL exposure (Figure 
4.2D). 
4.3 AMG 479 inhibits p-AKT in HT29 and HTOXAR3 cell lines, but induces apoptosis 
only in HT-29 cell line 
                 When MMP-7 was silenced  in HTOXAR3 there was a partial reversion in OXL 
resistance, but not at the level of HT-29, suggesting that mechanisms in addition to MMP-7 
could  contribute to OXL resistance acquisition in HTOXAR3 cells (Figure 4.3A). 
In vitro proliferation after 72 h exposure to individual drugs or a combination of them was 
assessed by MTT assay. Oxaliplatin primarily affects the HT-29 cell line. Sorafenib affects 
both HT-29 and HTOXAR3 cell lines equally, while panitumumab did not affect cell 
proliferation. AMG479 inhibited cell proliferation notably, and especially in HTOXAR3 
cells. The effect of the combination of AMG479 plus sorafenib and oxaliplatin induced a 
maximum cytotoxicity in both cell lines (Figure 4.3B). 
               To investigate the effects of their drug in AKT and IRS-1 phosphorylation 
inhibition, they treated HT-29 and HTOXAR3 cells with AMG479, a monoclonal antibody 
against IGF-1R and TIMP-1, a MMP inhibitor. they observed that AMG479 and TIMP-1 
inhibited p-IRS and p-AKT after IGF-1 stimuli. When they combined AMG479, TIMP-1 
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and sorafenib, they observed that p-IRS-1 and p-AKT inhibition was induced principally 
by AMG479. When they studied apoptosis they observed that the triplet combination of 
TIMP-1, AMG479 and sorafenib induced maximum apoptosis (in terms of PARP and 
caspase 3 cleavage) in the HT29 cell line, but did not show effects in the HTOXAR3 cell 
line (Figure 4.3C). 
 
 
 
Figure 4.2. Activation of IGF-1R/PI3K-AKT pathway, in cells chronically treated with 
oxaliplatin, is due to increase of MMP7 and IGFBP degradation  
(A) LoVo, LoVOXAR3, HT-29 and HTOXAR3 cells were treated with increased doses of 
OXL. MMP7 levels were analysed by ELISA method and WB after 48h after therapy. 
(B) HT-29 and HTOXAR3 cells were treated with OXL (20mM) and collected at indicated 
times. P-IRS-1, p-AKT, IGFBP-2 and IGF1R expression was assessed by western blot. 
C) Downstream effects on p-MAPK and p-AKT after different doses of OXL treatment 
(0.2, 2 and 20 mM) in LoVo, LoVOXAR3, HT-29 and HTOXAR3 cell lines. 
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    D) HT-29 and HTOXAR3 cells were treated with OXL (20mM) and phospho-AKT 
inhibition     was analyzed at 1 hour after therapy. 
 
 
 
Figure 4.3  The IGF-1R inhibitor AMG479 combined with sorafenib prevents IRS-1-AKT 
signaling but not apoptosis in HT-OXAR3 OXL cells lines 
A) MMP7 was silenced and the effect on OXL-resistance was evaluated by MTT. 
B) Cytotoxic effects in parental HT-29 cell line and the resistant HT-OXAR3 cell line were 
analyzed after IGF-1 stimuli with oxaliplatin (5mM), panitumumab, (1mM), sorafenib 2 (mM) 
, and AMG479 (5mM), and different combinations of these drugs. 
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C) Phosphorylation of IRS-1 and AKT were assessed in parental HT-29 and resistant HT-
OXR3 cells treated with AMG479, TIMP-1 and sorafenib. 
D) Effects on apoptosis (PARP and caspase 3) at 48 hours, in parental HT-29 cell line and 
the resistant HT-OXAR3 cell line were analyzed after sorafenib, TIMP-1 and AMG479. 
 
4.4  IGF-1R, p-IGF-1R and caveolin-1 are located differently in HT-29 and HTOXAR3 
cell lines 
                It has been observed that IGF-1R was located in the nucleus in HTOXAR3 cells but 
this wasn’t detected in HT-29 cell line (Fig 4.4A). By confocal microscopy they observed that 
IGF-1R membrane expression was more intensive in HTOXAR3. they also studied caveolin-1 
as a possible protein implicated in the internalization of IGF-1R. Caveolin-1 is located mainly 
in the cytoplasm of HT-29 but in a sparse manner. In HTOXAR3 cells, caveolin-1 was 
abundantly located in the peri-nuclear area. In HTOXAR3 there is a fraction of cells clearly 
showing p-IGF-1R expression and activation in the nucleus, but this nuclear pattern was not 
observed in the parental cell line (Figure 4.4B and Fig 4.4 
               A tissue block of HT-29 and HTOXAR3 cell lines were performed  to study cells 
characteristics with conventional immunohistochemistry. Differences were observed in the 
percentage of positive cells, being higher in HTOXAR3 (90%) compared to the parental cell 
line (30%). There were no major differences in the intensity of MMP7 expression between 
HT-29 and HTOXAR3 cell lines, with both cell lines showing strong cytoplasm expression. It 
has been observed that HTOXAR3 expressed p-IGF-1R in moderate-to-intense membrane and 
dot-like peri-nuclear patterns, compared to HT-29 cell lines, which also express p-IGF-1R as 
membrane and in the form of dot-like peri- nuclear patterns, but with a weak intensity. These 
immunohistochemical results confirmed the data obtained with confocal microscopy.  (Fig 
4.4C) 
4.5  Phospho-IGF-1R in the nucleus is not inhibited in HTOXAR3 cell line by IGF-1R 
inhibitors 
              To further extend our findings, we examined by confocal microscopy the capacity of 
the tyrosine kinase inhibitor of IGF-1R AMG479 and AEW541 in HT-29 and HTOXAR3 cell 
lines to avoid nuclear translocation of IGF-1R. In HT-29 and HTOXAR cell lines, IGF-1R 
was inhibited in the membrane (Figure 5A and Supl. Fig 4.5). P-AKT was inhibited with and 
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without IGF-1 stimuli after AMG479 inhibition (Figure 4.5B). Despite p-IGF-1R membrane 
inhibition, p-IGF-1R was also located and remained in the nuclear area in the HTOXAR3 cell 
line (Figure 4.5C). 
                 From November 2010 to December 2011, 113 consecutive mCRC patients were 
screened in 24 Spanish Hospitals in the ongoing prospective PULSE trial (NCT0128833) for 
p-IGF-1R (p-1316) MMP7 expression. Patients defined as DP should express MMP-7 (++ or 
+++ intensity in >66% of tumour cells) and p-IGF-1R (++ or +++ intensity in >66% of tumour 
cells); 48% of cases were positive for p-IGF-1R. Phospho-IGF-1R positive cases had different 
patterns of staining: peri-nuclear in 76%, 11% nuclear and only 13% membrane-apical 
staining. We found that tumours with positive p-IGF-1R expression, independently of the 
pattern of staining, had higher MMP7 co-expression (59%) compared with negative cases 
(13%, p<0.0001) (Figure 6). 
 
Figure 4.4 IGF-1R, p-IGF-1R (p-1316) and caveolin-1 are located differently in HT-29 and 
HTOXAR3 cell lines 
(A). IGF-1R expression in the cytoplasm and in the nucleus was assessed by Western blot 
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(B1) Location of IGF-1R was assessed in the resistant HTOXAR3 and the parental HT-29 cell 
line with confocal microscope 
(B2) Location of p-IGF-1R was assessed in the resistant HTOXAR3 and the parental HT-29 
cell line with confocal microscope. 
(B3) Location of caveolin-1 was assessed in the resistant HTOXAR3 and the parental HT-29 
cell line with confocal microscope. 
(C1) Location of p-IGF-1R in HT-29 and HTOXAR cell lines with a cell tissue block 
(C2) Location of MMP7 in HT-29 and HTOXAR cell lines with a cell tissue block 
 
 
 
Figure 4.4  IGF-1R, p-IGF-1R (p-1316) and caveolin-1 are located differently in HT-29 and 
HTOXAR3 cell lines 
 (A1) Location of caveolin-1 was assessed in the resistant HTOXAR3 and the parental HT-29 
cell line with confocal microscope 
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(B2) Location of p-IGF-1R was assessed in the resistant HTOXAR3 and the parental HT-29 
cell line with confocal microscope. 
(B3) Location of IGF-1R was assessed in the resistant HTOXAR3 and the parental HT-29 cell 
line with confocal microscope. 
 
 
  
 
Figure 4.5: HT-29 and HTOXAR3 cell lines were treated with the IGF-1R monoclonal antibody 
(AMG479) and an IGF-1R tyrosine kinase inhibitor (AEW541).  Changes in IGF-1R and p-IGF-1R 
(1316) were assessed with confocal microscopy. 
A: IGF-1R expression with and without IGF-1 stimuli in HTOXAR cell lines after AMG479 treatment.  
B:  p-AKT expression with IGF-1 stimuli with and without IGF-1 stimuli in HT-29 and HTOXAR cell 
lines after AMG479 treatment.  
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C: p-IGF-1R (1316) expression with and without IGF-1 stimuli in HTOXAR cell line after AMG479 
and AEW541 treatments.  
 
 
 
 
 
 
Figure 4.5 (supl): HT-29 cell line was treated with the IGF-1R monoclonal antibody 
(AMG479) and an IGF-1R tyrosine kinase inhibitor (AEW541).  Changes of p-IGF-1R (1316) 
were assessed with confocal microscopy. 
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5- Discussion 
                    Acquisition of drug resistance is the main hindrance to effective treatment. In 
spite  of   Discovery of a new therapies in colorectal cancer, nearly all patients become chemo-
resistant. The present study focused on whether the status of IGF-1R signaling, known to be 
involved in colorectal cancer progression and growth, contributes to OXL-resistance. The 
study  presents two major findings that might represent a previously uncharacterized 
mechanism of IGF-1R-related acquired resistance. First, increase of MMP7 in HTOXAR3 
contributes to IGF-1R activation and OXL-resistance. Second, HTOXAR3 cell line showed 
constitutive activated IGF-1R, in part located in the nuclear area, compared with HT-29 and 
this location probably contributes to IGF-1R resistance. 
                    In LoVo cell lines, AKT phosphorylation was repressed after low OXL exposure 
and this effect was durable (>24h). In HT-29, although p-AKT inhibition was observed at 1 
hour with high doses of OXL, this effect was not sustained at 24 hours. The levels of MMP7 
obtained in HT-29 after 24h OXL-exposure were similar to the basal levels in HTOXAR3 and 
to those achieved by Miyamoto et al., (2004),  in HT-29 when 200 ng/mL MMP7, was added 
to artificially engage p-IGF-1R (8). In the HT-29 cell line, MMP7 increased at 24 hours after 
OXL treatment, achieving levels similar to those observed in HTOXAR3. hypothesizing that 
IGFBP-2 degradation can be due to increased MMP7. These very high levels of MMP7 are 
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then able to activate IRS-1/AKT pathway and preclude the effect of OXL. The study describes 
that this mechanism of IGF-1R activation by MMP7 is acquired after chronic OXL exposure. 
Since MMP7 silencing can reverse OXL-resistance in HTOXAR3, at least partially, MMP7 
appears to play a crucial role in OXL-acquired resistance. These results are in accordance with 
published data by Hörndler et al., (2011), showing that this specific pattern (MMP7+/p-IGF-
1R+) reflects a subset of patients who are clinically resistant to irinotecan and cetuximab. 
                  IGF-1 regulates caveolin-1 and IRS-1 interplay in caveolae (Panetta et al., 2004). 
The mechanism by which caveolin-1 expression is increased in OXL-resistant cells 
(LoVOXAR3 and HTOXAR3) remains unexplained. Several reports indicate that in chemo-
resistant colorectal cancer cell lines, caveolin-1 expression is increased (Bender et al., 2000), 
probably as a consequence of detachment (i.e., due to low levels of IGFs) and an ability of 
tumour cells to survive in the absence of ECM-derived signaling (Ravid et al., 2005). Gallego 
et al., (2009) has also reported that patients with ACRC treated with chemotherapy show 
lower levels of IGF-1 and IGFBP-3 at tumour progression, concomitant with increased 
MMP7. 
                      Two types of IGF-1R induction mechanisms have been recently described. An 
acute induction (as rapid as 48h) has been described with erlotinib in cell lines addicted to 
EGFR/AKT pathway (Sharma et al., 2010). Interestingly, the cell subpopulation with EGFR 
TKI tolerance also exhibits reduced sensitivity to cisplatin. additionally, IGF-1R could be 
induced with AKT inhibitors in HER-2/AKT dependent cell lines, and also in cell lines 
lacking HER-2 amplification but AKT-dependent, resulting in FOXO-dependent nuclear 
translocation and RTK driven signaling (Chandarlapaty et al., 2011). A second mechanism of 
IGF-1R induction in RAF-MEK dependent cells is mediated by down-regulation of IGFBP 
and a PI3K-AKT switch after chronic treatment with BRAF inhibitors (Villanueva et al., 
2010). A third mechanism that occurs in colorectal cells tolerant to chronic OXL as a 
consequence of MMP7 increase and  suggest IGF-1R/IRS-1/AKT engagement. A similar IGF-
1R/IRS-1/AKT induction has been shown by IGFBP down-regulation after chronic erlotinib 
treatment (Guix et al., 2008). All these data suggest that IGF-1R induction and activation is a 
mechanism widely used by different types of tumours to acquire multi-drug resistance. 
                   Simultaneous treatment with sorafenib and AMG479 induces maximum cytotoxic 
effects and AKT inhibition, but there was a modest apoptotic effect in HTOXAR3, suggesting 
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apoptotic-resistant pathways which are at least partially AKT independent. Therefore we 
assessed whether apoptotic resistance could be due to differences in p-IGF-1R location.  
observing that despite membrane p-IGF-1R inhibition with AMG479 and AEW541 in HT-29 
and HTOXAR3 cell lines, there is a persistence of p-IGF-1R in the nucleus in the latter. 
speculating that phosphorylated IGF-1R in HTOXAR3, concomitantly with caveolin-1 
increment could induce SUMOylation (Deng et al., 2011), allowing the translocation of part of 
the p-IGF-1R to the nucleus (Sehat et al., 2010). It has been reported recently that IGF-1R 
could work as a transcriptional enhancer in the nucleus by means of direct interaction with 
chromatin (Aleksic et al., 2010) and therefore mediate IGF-1R resistance in the nucleus by an 
AKT-independent pathway (Kulik and Weber, 1998; Remacle-Bonnet  et al., 2007). 
                   The data presented  provide a strong rationale to explain why anti-IGF-1R 
compounds have low efficacy in chemo-resistant patients (Reidy et al., 2010;  Eng et al., 2011; 
Watkins et al., 2011). Meaningfully, some colorectal cancer patients show initially p-IGF-1R 
in the nucleus, suggesting that a subset of colorectal cancer patients could be coherently 
resistant to anti- IGF-1R compounds and OXL (Cuatrecasas et al., 2011). 
                   Matrilysin (MMP7) is known to activate pIGF-1R through IGFBP-3 degradation, 
and consequent releasing of IGF-1. In ACRC patients the co-expression of MMP7 and pIGF-
1R (double positivity, DP) has been shown to correlate with poor prognosis in KRAS-
WT patients treated with anti-EGFR (Cetuximab) in retrospective analyses (Hörndler et al., 
2011). We recently performed a prospective clinical trial to validate those findings. Screening 
196 mCRC patients treated with anti-EGFR (Panitumumab) in 24 Centers in Spain came out 
with a response rate of 56% in non-DP and of 67.6% in DP patients (p=0.18) and median PFS 
(95% CI) was 7.1 months (5.1-9.6) in non-DP and mPFS 9.9 months (8.1-15, p=0.19) in DP 
patients. Median overall survival (mOS) was 28.1 months (25.6-30) in non-DP patients vs 19.9 
months (16.1-27.6, p=0.004). The multivariate (PS, LDH, age and sex) adjusted HR for 
mortality was 2.81 (1.33-5.96, p=0.0069). The results of this prospective study validates 
MMP7/pIGF1R as a novel strong prognostic biomarker in ACRC-KRAS-WT patients, treated 
in first-line with FOLFOX-6 plus anti-EGFR. 
                   Overall, these results suggest that our anti-pIGR1R antibody could be considered a 
biomarker of response to immunotherapy in patients with ACRC.  
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6- Conclusion and Recommendations 
These results have provided a full functional description of MMP7 and IGF-1R roles and 
interactions on the acquired resistance after chronic OXL exposure. Accordingly, nuclear IGF-
1R location may contribute to intrinsic and acquired resistance to both OXL and anti-IGF-1R 
therapies. As this specific resistant pattern can be optimally evaluated by 
immunohistochemistry, with a specific antibody (IGF-1R-p-1316) (Rubini et al., 1999), we 
believe that our findings may allow potential new strategies to select patients with ACRC who 
are sensitive to chemotherapy and anti-IGF-1R compounds. 
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Effect of folinic acid on proliferation and survival of HL-60 pro-myelocytic cells 
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1- Introduction and Review of literature 
1.1  Folates: 
1.1.1 Chemistry and properties: 
              Folate, commonly known as vitamin B9 is a water soluble vitamin, existed naturally 
in a wide variety of foods such as green vegetables, and encompasses a large  family of 
compounds with same chemical structures and nutritional properties( Gropper et al ., 2005).  
Folate, mediates the transport of one- carbon moieties crucial for the de novo biosynthesis of  
purine and thymidylate, and thus is a fundamental factor for DNA synthesis, replication, 
repair, methylation reaction and deficiency of vitamin which has been shown to play a major 
role in the causation of various disorders including anemia, atherosclerosis, adverse pregnancy 
outcomes,  and cancer( Kim, 2007). It’s demonstration was dated back to 1931 by Lucy Willis 
who noticed that, extracts of liver and yeast when administered orally, were found to be 
effective in treating tropical macrocytic anemia( Willis, 1931; Shane, 1995). Subsequently, the 
specific  nutritional factor in charge of the observed therapeutic benefit was isolated from liver 
extracts and the chemical structure was established to be N-[4-{[(2-amino-4-hydroxy-6- 
pteridinyl)methyl]amino}bonzoyl]glutamic acid. Moreover, the name pteroylglutamic acid’ 
was being proposed by the discovering scientist( Angier et al., 1946). the name folic acid was 
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concurrently proposed for nutritional factor with the similar nutritional properties that, had 
been isolated from spinach, with the word ‘ folic’ derived appropriately  from Latin- folium( 
leaf)( Mitchel et al., 1941). The chemical structure of folic acid consists of three distinct 
components: para-aminobenzoic acid (PABA) is attached at one end to a 2-amino-4-hydroxy-
pteridine (pteridin) moiety via a methylene group, and at the other end to one L-glutamic acid 
(glutamate) residue via a peptide bond( Shane, 1995).  
 
 
   Figure 1.1 chemical structure of folic acid ( pteroylmonoglutamate abbreviated as  PteGlu). 
Folic acid consists of three distinct components: the pterine or ( pteridine) ring, which is 
conjugated to PABA( para- aminobenzoic acid by a methylene bridge which together are  called 
pteroic acid , which is in turn joined to glutamic acid ( glutamate) residue via a peptide bond 
reproduced from ( Kim, 2007). 
Folic acid is simply considered as parent structure of this large extended vitamin family 
existed as a stable, synthetic analogue that is found not only in supplement, but also added in 
fortified food. The term folate designate to the naturally occurring type of vitamin that is 
basically differ from folic acid in the oxidation rate of pteridine ring. Tetrahydrofolate THF is 
constituted of pteridine  core ring system (2- amino- 4- hydroxyl – pteridine) that is linked in 
one side to p – aminobenzoic acid (also known as pteroic acid) via a methylene bridge from 
the C – 6 position of pyrazine ring, therefore, forming tetrahydropteroic acid. An additional 
link joins glutamate to the p- aminobenzoic acid with 1 to 9 residues. The pyrazine ring is 
completely reduced at the 5, 6, 7 and 8 positions forming the biologically active form, referred 
to as 5,6, 7,8 – tetrahydrofolate( THF). Dihydrofolate( DHF) is formed through two 
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consecutive reduction of 7 and 8 positions, using two molecules of Nicotinamide adenine 
dinucleotide phosphate( NADPH). Several other bioactive compound derive from this basic 
structure( Donnelly, 2001). Additionally, natural occurring forms of folate differ based upon 
the one carbon units attached at the N- 5 and / or N- 10 positions of THF(table 1.1) (Gropper 
et al ., 2005).  In terms of stability, the reduced forms of folates depend upon the substituent of 
one- carbon. Nonetheless, reduced folates are categorically less stable compared to folic 
acid(Shane, 1995). 
 
 
 
Table 1.1 one- carbon substitution of tetrahydrofolates 
Folate derivative One- carbon substitution 
5- FormylTHF -CHO 
5, 10- MethenylTHF =CH 
5, 10 MethyleneTHF =CH2 
5- MethylTHF -CH3 
10- FormylTHF -CHO 
5- FormininoTHF -CH=NH 
   
1.1.2  Folinic acid: 
                  Folinic acid, 5-formyltetrahydrofolate (5-CHO-THF), also known as leucovorin( 
LV) is usually responsible of 3- 10% of total intracellular folate in mammalian cells. 
Nevertheless its metabolic function in cells has not been fully elucidated(Stover and Schirch, 
1990). Folinic acid is  formed from 5,10-methenyltetrahydrofolate (5,10-CH=THF) by a 
hydrolytic reaction catalyzed by serine hydroxymethyltransferase( SHMT) and whereby serine 
interconverted into glycine(Stover and Schirch, 1990; Holmes, and Appling, 2002).Moreover, 
spontaneous chemical hydrolysis of 5,10-CH=THF might be a minor extra source(Baggott, 
2000). 5-CHO-THF is not only considered as the most stable naturally occurring folate, but 
also the most enigmatic, as it is solely doesn’t serve as a cofactor in one- carbon metabolism. 
5-CHO-THF in place is a potent inhibitor of SHMT and many other folates dependent- 
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enzymes in vitro( Stover and Schirch, 1993; Roje., 2002). Furthermore, methyltetrahydrofolate 
synthase(MTHFS) is only enzyme known to metabolize 5- CHO-THF, by catalyzing the ATP- 
dependent and irreversible conversion of 5-CHO- THF into 5,10- CH=THF. MTHFS is found 
in the cytoplasm of the rabbit liver, whereas human liver accommodates about 85% of the 
MTHFS activity in the cytoplasm and 15% in the mitochondria(Maras et al., 1994; Bertrand et 
al., 1995). The joined enzymatic activities of MTHFS and SHMT make up the futile cycle that 
not only  may reduce cellular 5- CHO-THF but also regulate SHMT activity(Stover and 
Schirch, 1993). The cytoplasmic one- carbon metabolism is accounted for the synthesis of 
purine, thymidylate, methionine and many subsequent S- adenosylmethionine dependent 
methylation reaction. Moreover, there is growing evidence that mitochondrial folate 
metabolism is mainly accountable for the production of formate hence mitochondrial derived 
formate is the source of one- carbon units requisite for cytoplasmic folate – dependent 
anabolic reactions(Appling, 1991). The key source of one- carbon units in the form of formate 
are produced from serine in a reaction catalyzed via mSHMT, nonetheless, formate can be 
generated in the mitochondria through glycine in cells which contain GCS(Cowin, 1996).the 
role played by mitochondria in generating one- carbon units for cytoplasmic folate indicates 
that cSHMT may not serve a chief role in the generation of one- carbon units. However, there 
is a mass  of evidence indicating that cSHMT is not a resourceful of one- carbon units for 
cytoplasmic metabolism. Interestingly, a study by Narkewicz et al.,(1996) on Chinese hamster 
cells(CHO) which lack mSHMT activity have revealed that (CHO) cells deprived in mSHMT 
activity amass 15- fold increased intracellular serine concentrations over wild type CHO cells. 
Not surprisingly, CHO deficient mSHMT activity are auxotrophic for glycine. In spite of 
accumulation of intracellular serine, the net metabolic flux via cSHMT enzyme in CHO cells 
deprived in mSHMT activity is in the direction of serine synthesis. Accordingly, the prime 
role of cSHMT may not only be to generate glycine or one- carbon units but also instead may 
have other metabolic functions including the synthesis of 5- CHO- THF(Girgis et al., 1997).       
1.1.3  Folate metabolism 
1.1.3.1  Overview: 
              Folate is primarily transported into the cell in form of monoglutamate. Cellular folate 
leak out is prevented through polyglutamylation, an energy dependent reaction whereby up to 
9 glutamate units are added to the γ- carboxyl group of the glutamate tail, a reaction catalyzed 
by the  folyl-poly-γ-glutamate synthetase enzyme(FPGS)( Shane, 1989). The activity of FPGS 
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has been well- characterized in many cells, and it shows affinity for THF as the primary folate 
substrate for polyglutamylation. Since the prime folate obtained from the diet are naturally 
occurring 5- methylTHF and synthetic folic acid, the cellular enzymes capable of converting 
these folate forms to THF, namely, methionine synthase(MS) and dihydrofolate 
reductase(DHFR), are seen as rate limiting for cellular folate accumulation(Lucock, 2000). 
The FPGS activity is antagonized by the lysosomal activity of  γ- glutamyl hydrolase(GGH)( 
also referred to as folylpoly- γ-glutamate carboxypeptidase) which catalyzes the hydrolysis of 
these  terminal γ-glutamyl residues from polyglutamylated folates(Ifergan et al., 2008). 
Intracellularly, five major folate- dependent one- carbon transfer reactions have been fully 
characterized: the interconversion of serine to glycine, the degradation of histidine, the 
synthesis of thymidylate, methionine and purine nucleotides. Additionally, the methyl or 
formyl groups contributed by the dietary intake of 5- methyl THF and 5- formylTHF, the one- 
carbon units utilized in folate- dependent one- carbon metabolism are mainly derived from the 
β- carbon of serine which is converted to glycine via the enzyme 
serinehydroxymethyltransferase(SHMT), as it moves the β- carbon group to a THF cofactor 
creating 5,10- methylenetetrhydrofolate(5,10- methylene THF). The formimino group resulted 
from the breakdown of histidine, the carbon moiety generated by glycine decarboxylase in 
mitochondrial degradation of glycine, the methyl moiety produced in the catabolism of choline 
to first sarcosine then finally to glycine, and cellular formate have all been found as an 
additional sources of one- carbon units(Lucock, 2000). Folates play a major role in the 
biosynthesis of pyrimidine and purine nucleotides, fundamental in the new synthesis of DNA 
and RNA as well as in the repair of damaged DNA. In purine biosynthesis, two one- carbon 
units from 10- formyl THF are placed in the first place to glycinamide ribonucleotide(GAR) 
via GAR transformylase enzyme forming N- formylglycinamide ribonucleotide(FGAR), and 
latter to aminoimidazol-4 – carboxamide ribonucleotide(AICAR) through AICAR 
transformylase enzyme forming N- formylaminoimidazol-4 – carboxamide 
ribonucleotide(FAICAR).the transferred formate moiety become carbons 8 and 2 of the purine 
ring. In the biosynthesis of pyrimidine, the methyl moiety of 5, 10- methylene THF is 
transported unto deoxyuridylate monophosphate(dUMP) forming deoxythymidylate 
monophosphate(dTMP) and dihydrofolate(DHF) in  a reductive methylation interaction 
catalyzed by thymidylate synthase(TS) enzyme. DHF is reduced back unto THF via DHFR 
enzyme, moreover, the cofactor reduced Nicotinamide adenine dinucleotide 
phosphate(NADPH)(Kompis and Islam, 2005).not surprisingly, folates serve paramount 
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important biological function in the remethylation of homocysteine(Hcy) to form methionine, 
which is afterward converted unto S-  adenosylmethionine(SAM), the sole methyl donor for 
all intracellular methylation reactions including DNA, RNA, protein, lipids and toxins. In 
remethylation of Hcy, firstly, 5,10- methylene THF is reduced to 5- methyl THF in an 
irreversible reaction catalyzed by methylenetetrhydrofolate reductase enzyme(MTHFR)(Green 
et al., 1988). 5- methyl THF transfers methyl group to Hcy creating methionine and THF via 
MS enzyme using B12 as cofactor(Stokstad and Koch, 1967).  
                 The biological functions played by different type of folate species need 
sophisticated interconversion cycles catalyzed by many different enzymes. Since these cycles 
intersect many pathways, it is fully appreciated that the interconversion of folate species used 
as a mechanism whereby aspects of metabolism are regulated. In proliferating cells, DNA 
synthesis is pretty important, moreover expression of the enzyme TS peaks during the 
Stationary phase of the cell cycle indicate an adequate supply of thymidylate. Increased 
thymidylate synthesis leads to elevated concentrations of DHF, which has been found to be an 
allosteric inhibitor of the MTHFR enzyme. Inhibition of MTHFR ensures that intracellular 
pools of 5,10- methylene THF are used in purine and pyrimidine synthesis rather than 
committed toward methionine formation(Matthews and Baugh, 1980). signaling plentiful 
methylation capacity, inhibiting MTHFR and therefore, the formation of 5- methyl THF. In 
reverse, increased levels of 5- methyl THF, ensuring decreased levels of SAM thus reducing 
methylation capacity, have been known to inhibit several non- critical methyltransferase 
enzymes, therefore conserving limited SAM for essential methylation reaction(Wagner et al., 
1985; Lucock, 2000). As had already known the complex metabolism, regulation and 
interconversion of folate species in concert with the crucial roles that, played by folates in 
biosynthetic reactions. It is well evident that, folate nutrition is intimately linked to human 
health and disease.   
1.2  Cell cycle: 
             Four phases have been well defined in eukaryotic cell division cycle: gap 1(G1) 
during which the cell conducts a series of checks before entering the (S) phase, DNA 
stationary phase (S), where DNA synthesis is  occurred), gap 2(G2), similarly the cell check 
its readiness to proceed to mitosis and mitotic phase(M), is when the cell actually divides( 
Howard and  Pelc, 1953).passing through the cell cycle is tightly controlled and neatly 
coordinated by a large family of cyclin dependent kinases(cdk), heterodimer complexes 
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containing internal catalytic kinase domain beside a regulatory cyclin domain and 
subsequently, forming a family divided into two groups based upon their roles in cell cycle 
progression and transcriptional regulation(Meyerson et al., 1992; Sausville, 2002). members of 
the first group comprise epicenter part of the cell cycle machinery, which include cyclin D- 
dependent kinases4 and 6 and cyclin E- cdk2 complexes as well, which sequentially activate 
the retinoblastoma  protein(Rb), to facilitate the G1→S transition. Cyclin kinases are 
choreographed and activated by binding to its respective cyclin proteins(Sherr, 1994; Morgan, 
1995). Regulated via phosphorylation, controlled by cdk- activating kinases (CAK; cyclin 
H/cdk7/ MAT1), and inhibited via cdk inhibitors by their association with cyclins  and 
endogenous Cip/Kip or INK4 (inhibitor of cdk4) inhibitors (Solomon, 1993; Hengst et al., 
1994; Reed et al., 1994; Sherr and Roberts, 1995;  Harper and Elledge, 1998 ). The cdks finely 
regulate biochemical pathways, or checkpoints, which combine mitogenic and growth 
inhibitory signals and track chromosome integrity(Murray, 1992; Hartwell, 1992). The cyclins 
serve paramount regulatory role in this process as they are synthesized and catabolized over 
relatively short periods of time at sharply defined points of the cell cycle(Reed, 1992; Sherr, 
1993).Intriguingly, cyclin A- dependent kinases 2, 1 along with cyclin B- cdk1 complexes are 
prerequisite for orderly progression and Passing through G1 into S and the G2→M transition, 
respectively(Pines, 1991; Sherr, 1994). In cancer cells, both altered expression of cdk and their 
modulators as well as overexpression of cyclins and loss of expression of cdk inhibitors, 
subsequently, deregulated cdk activity, providing a selective growth advantage(Sherr, 1996;   
Hall and Peters, 1996). Paradoxically, cdks governing the transitions between cell cycle phases 
transcriptional cdks, containing cyclin H-csk7, and cyclin T- cdk99pTEFb), promoting 
initiation and elongation of nascent RNA transcript via phosphorylating the carboxy- terminal 
domain(CTD) of RNA polymerase II(Prelich, 2002; Palancade and Bensaude, 2003).      
              On one hand at the cellular level, each single cell must go through the cell cycle in a 
tidily and well controlled fashion where the multiple steps connected with each other must be 
successfully and efficiently completed prior to the next. On the other hand, at the tissue level, 
there is experimental as well as clinical data suggesting similar progression through the cell 
cycles in specific organ entering S- phase and mitosis at specific times of the day(Scheving, 
1984).  
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1.2.1  The G1→ S transition: 
             The retinoblastoma susceptibility protein(Rb), plays a pivotal role in the G1→ S 
transition. As in its hypophosphorylated state, Rb abrogates progression from G1→S by 
interacting with E2F transcription family members. This reaction blocks the transcriptional 
activation of E2F, furthermore, actively inhibits transcription via recruiting histone 
deacetylases to the promoters of genes required for entering  S- phase(Weinberg, 1995; 
Harbour and Dean, 2000). During cell cycle progression, Rb is inactivated through sequential 
phosphorylation directed by cyclin D- dependent kinases4,6 and cyclin E- cdk2 complexes. In 
response to mitogenic stimulation cells produce D- type cyclin which merge with cdks4 and 6, 
a process that necessitates contribution of a cip/kip family member. Cip/ kip family members 
are not only promote activity of cyclin D-dependent kinases, but also are potent inhibitors of 
cdk2(Lundberg and Weinberg, 1998; Harbour et al., 1999; Sherr and Roberts, 1999). 
Accordingly, cyclin D- dependent kinases promote G1 progression through phosphorylating 
Rb, then relieving transcriptional inhibition via the Rb- E2F complex, moreover, by 
sequestering Cip/Kip proteins, promoting activation of cyclin E- cdk2, which directed Rb 
phosphorylation dissociates the binding of Rb to E2F, letting on E2F activation, as well as 
transcription of genes requisite for S- phase entry and furtherance including cyclin E per 
se(Botz et al., 1996; Geng et al., 1996). Much as Rb is the main target of cyclin D- dependent 
kinases, cyclin E- cdk2 activates other targets, including p27 
kip1
(Sheaff et al., 1997; Vlach et 
al., 1997).conjointly, G1 progression is regulated by members of the INK4 family, act as 
specific inhibitors of cdks4 and 6. p16 INK4A amasses as long as cells age inducing G1 arrest 
during senescence by assembling with cdks4  and 6 promoting freeing D- type cyclins. 
subsequently, damaging of D- cyclins and the redistribution of Cip/Kip proteins to cdk2 
contributes to G1 arrest(Jiang et al., 1998; Sherr, and  Roberts, 1999).  
1.2.2.  S- phase progression: 
               Following phosphorylation of Rb, directed by cdk during G1, E2F restored its 
activity, and later freed to bound its heterodimeric partner, DP-1, mediates,  transcription of 
genes needed for S phase. This transcription is temporarily  activated. Tidily and orderly S- 
phase succession necessitates the downregulation of E2F-1 activity, partly, achieved by cdk- 
mediated phosphorylation(Krek et al., 1994; Dynlacht et al., 1994; Xu et al., 1994; Kitagawa 
et al., 1995). Repression of cdk activity during S Phase leads to inappropriately persistent E2F, 
known to cause S- phase delay and apoptosis as well.E2F-1- induced apoptosis can happened 
due to both p53- dependent and p53- independent mechanisms. The very latter involving the 
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activities of E2F-1 transcriptional targets, such as p 73, Apaf-1, caspase 3; inhibition of Mcl-1; 
or the capacity of E2F-1 to interact with death receptor and nuclear factor- kappa B(NF-ĸB) 
pathways(Phillips et al., 1999;  Phillips and Vousden, 2001; Croxton et al., 2002).  
1.2.2.1  Phosphorylation of E2F-1: 
                E2F-1 is phosphorylated by several cdk holoenzyme during S and G2 phases, 
furthermore, they take part  in the appropriately timed neutralization of its activity. Cyclin A- 
cdk2 stably interacts with N- terminus of E2E-1 , and mediates the phosphorylation of E2F-1( 
most likely at Ser
307
), and DP-1 as well, which represses the DNA binding activity of the 
dimer(Krek et al., 1994; Kitagawa et al., 1995). Phosphorylation by cyclin A-cdk1 at Ser375 
may well promote the formation of Rb-E2F-1 complexes, contributing to the turning off of 
E2F-1 activity late in cell cycle. In such a way that,  repression of cdk1 would allow the 
persistence of E2F-1 release of Rb(Chen et al., 1999). Ultimately, the activity of kinase is 
associated with general RNA polymerase transcription factor IIH(TFIIH) multisubunit protein 
complex, cyclin H-cdk7/MAT-1, activates E2F-1 at Ser
408
 and Thr
433
, precondition for 
ubiquitination and degradation. Mutation of these regions to alanine greatly enhances E2F-1 
stability(Vandel and  Kouzarides, 1999). The targeting of E2F-1 phosphorylation through cdk 
repression may selectively, result in death among transformed cells. The disrupted cyclin D- 
cdk4/6- INK4- Rb pathway in tumour cell brings about high level of E2F-1 activity. A small 
reduction in cdk activity during S phase may result in persistence of E2F activity, which has 
minimal effect on normal cells, however it may leave transformed cells with unsuitably 
persistent E2F activity at a high level enough to excel the threshold necessary to induce 
apoptosis(Chen et al., 1999).  
1.3  Ultraviolet radiation UV: 
                  UV radiation is a non – ionizing form of radiation, located in a region of 
electromagnetic spectrum ranging between 100 nm to 400 nm wavelength. UV radiation is 
arbitrarily categorized into UV- A(315 nm to 400 nm), UV- B( 280 nm to 315 nm) and UV- 
C(100 nm to 280 nm)( Jo, 2005). Recently, according to the International Agency for the 
Research on Cancer,  both UV-A and UV-B has been classified as a class I carcinogen(El 
Ghissassi et al., 2009). Possibly, the middle wavelengths of UVB radiation are considered as 
the most important for cytotoxicity(Ichihashi et al., 2003). Whereas, UVC a highly energetic 
radiation is irrelevant from a public health perspective, as essentially all of it is absorbed by 
atmospheric ozone. However, studies on UVC radiation can be conducted using economic 
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germicide lights that emits chiefly at 254 nm, close the maximum for DNA 
absorption(Ichihashi et al., 2003).  
                  Cellular DNA is the prime target of UV radiation. Since the energy of UV light had 
been absorbed by a DNA double bond in pyrimidine bases( thymine and cytosine), brings 
about bond opening and subsequent reactivity with adjacent molecules. Unfortunately, if the 
neighboring base is another pyrimidine, a newly covalent bond establishes between them 
leading to the four membered cyclobutane ring of the pyrimidine dimer. Additionally, a single 
bond may establish between two carbon atoms on the cyclobutane ring leading to the so 
called”6-4(T-C) photoproduct(Lindahl and Wood, 1999; Sinha and Ha¨der,  2002; Dunkern 
and  Kaina, 2002;  Sancar et al., 2004;). Although the same lesions are caused by UVB 
radiation they account for about half the cytotoxicity, with the most of the rest attributed to 
oxidative damage to DNA along with other cellular targets. UVB and UVA generate 
considerable levels of reactive oxygen species(ROS), such as peroxides, singlet oxygen and 
transient hydroxyl radicals. damage induced by UVA radiation is mainly ascribed oxidative 
damage with generation of only insignificant levels of photoproducts such as pyrimidine 
dimers(Tyrrell and    Pidoux, 1986; Ichihashi et al., 2003).    
1.4  c-Myc proteins:  
               The Myc proteins are a basic- helix-loop-helix-leucine zipper(BHLH-ZIP) 
transcriptional factor playing paramount roles in cell growth as well as proliferation, thanks to 
their capacity to down-regulate or upregulate genes expression, that collectively induce 
cellular transformation. Additionally, cell cycle regulation.  Accordingly, Mutation, 
amplification, or activation of the Myc oncogene family is the most frequent events associated 
with cancer(Lüscher and Larsson, 1999; Fernandez et al., 2003; Levens, 2003;   Adhikary and 
Eilers, 2005; Eilers and  Eisenman, 2008). Furthermore, c-Myc is much often activated in 
acute myeloid leukemia(AML), playing pivotal role in the genesis of leukemia(Hoffman et al., 
2002; Renneville et al., 2008). Nevertheless, the expression of c-Myc protein in normal cells 
correlates with cell growth, whereas expression is deficient in quiescent cells but is rapidly 
induced upon the supplementation with growth factor. Interestingly, the half-life of c-Myc  is 
as short as 20-30 minutes indicating that, its level perturbations dynamically upon a broad 
range of cellular activities. Moreover, the  expression peaks 3-4 h following growth factor 
stimulation, and lower level found in cycling cell. Growth factor withdrawal at any point in 
cell cycle leads to prompt down regulation(reviewed in Mateyak et al., 1997; Chan et al., 
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2004). Furthermore, Mateyak et al.,(1997),  reported that c-Myc in rat fibroblast caused a 
distinct prolongation of cell doubling time, proposing a fundamental role c-Myc in regulating 
cell proliferation.   
                   To exert its function it is necessary that, Myc heterrodimerize with its respective 
partner Max, a stable and constitutively expressed ubiquitous protein. Myc and Max bind 
through their canonical BHLH-ZIP subunits, and consequently bind to E box DNA sequences 
containing the core consensus sequence CACGTG(reviewed in Grandori et al., 2000;  Amati 
et al., 2001).  Inhibition of c-Myc could be accomplished via the DNA binding activity of c-
Myc by disruption of c-Myc/Max heterodimerization(Dang, 1999). 10058-F4 is small 
molecule c-Myc inhibitor. Mediates its function by preventing the binding of c-Myc/ Max 
dimer, and resulting in inhibiting proliferation, cell cycle arrest and inducing apoptosis via 
mitochondrial pathway. Moreover it found to induce myeloid differentiation(Huang et al., 
2006).  
1.5  Apoptosis: 
1.5.1  Overview:         
                Apoptosis not only is an important process , but also is tightly regulated and 
controlled forms of cell death, presumably genetically programmed hence called programmed 
cell death that, takes place under different variety of physiological and pathological 
conditions. Historically, the term apoptosis is dated back to 1972 when Kerr, Wyllie and 
Currie described a morphologically definite form of cell death, albeit specific types of 
apoptosis had been explicitly described many years before( Kerr et al., 1972; Paweletz, 2001; 
Kerr, 2002). Our knowledge of the detailed mechanisms entailed in the process of apoptosis in 
mammalian cells is well known, thanks to the exhaustive investigation of programmed cell 
death that occurs during the development of nematode Caenorhabditis elegans( Horvitz, 1999). 
Intriguingly, in this organism 1090 of somatic cells are generated during the formation of adult 
worm. Among which 131 of these cells undergo apoptosis. These 131 cells die at specific 
points during the developmental process, which is fundamentally invariable between worms, 
displaying the astonishing accuracy and control in this system. Apoptosis has long since been 
recognized and accepted as a characteristic and important way of programmed cell death that, 
involves the genetically determined elimination of cell. Nonetheless, it is noteworthy that,  
other forms of apoptosis has been described, and other forms may yet be discovered(  
(Formigli et al., 2000; Sperandio et al., 2000; Debnath et al., 2005)  Apoptosis  has been 
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acknowledged to be of paramount importance for embryonic development, tissue homeostasis, 
neurodegeneration, autoimmune diseases, AIDS, carcinogenesis, cancer progression and 
murdering of cancer cells induced by chemotherapeutic drugs(Wyllie, 1980; Cohen, 1991; 
Ameisen, 1994; Kerr et al., 1994; Friesen et al., 1996; Gehri et al., 1996; Kusiak et al., 1996; 
Jacobson et al., 1997).  
1.5.2  Morphology of apoptosis: 
                Both light and electron microscopy have identified different diverse morphological 
changes that occur during apoptosis( Hacker, 2000).   Morphologically, apoptosis initially 
characterized by a change in the refractive index of the cell later ensued by cytoplasmic 
shrinkage and nuclear condensation. The cell membranes starts showing blebs or spikes( 
protrusions of the cell membrane), depending upon cell types. And at the last, these 
protrusions pinch off from the dying cells to form “ apoptotic bodies” furthermore, apoptotic 
cells stop maintaining phospholipid asymmetry in the cell membranes, and thus 
Phosphatidylserine externalized to the  cell surface( Hengartner, 1997; Williamson, 2000).The 
mitochondrial outer membrane ( MOM) undergoes changes which include loss of its 
electrochemical gradient, perhaps by forming  pores in MOM, moreover, substances such as 
cytochrome c leak from MOM into the cytoplasm. Finally, a nearby cells or macrophages 
engulf apoptotic bodies and dying cells. The apoptotic bodies does not initiate an 
inflammatory response, and only individual cells are affected by apoptosis in vivo. These 
morphological changes are attributed to a distinctive molecular and biomedical events 
occurring in an apoptotic cells, most remarkably, the activation of lysosomal proteolytic 
enzymes which in the course of time mediate the cleavage of DNA into oligonucleosomal 
fragments and the cleavage of a multitude of specific protein substrate, which establish the 
unity, integrity and shape of the cytoplasm or organelles(Saraste, 2000). Not surprisingly, the 
events of apoptosis are diametrically different from necrosis. The cytoplasm and mitochondria 
of necrotic cells balloon out, and ultimately the cells and many of its organelles lyse. There is 
no apoptotic body formation, and often necrosis affects groups of  neighboring cells. The 
necrotic cell remnants are phagocytosed by macrophages, and inflammatory responses are 
provoked in vivo(Leist and  Jäättelä, 2001). 
1.5.3  Molecular mechanism of apoptosis signaling pathways: 
                 Apoptosis is a complex,  multifaceted and highly efficient cell death program which 
requires interaction of multiple factors. The constituents of the apoptotic signaling plexus are 
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genetically encoded , moreover, are considered to be usually in place in nucleated cells ready 
to be triggered by death inducing stimulus( Ishizaki, 1995; Weil, 1996). Apoptosis can be 
caused and triggered by diverse type of stimuli from either outside or inside the cell, e.g. 
treatment with cytotoxic or irradiation, by deficient of survival signal, incongruous cell cycle 
signaling or by developmental death signal, by ligation of cell surface receptors, by DNA 
damage. Much knowledge of cell death has stemmed from genetic studies in the nematode C. 
elegans whereby several genes have been discovered([Hengartner, 1999). The proximate cause 
of apoptosis in C. elegans is the stimulation of cysteine protease ced- 3( is the single C. 
elegans member of a family of the caspases)  that is directed by its oligomerization at the 
activation protein ced- 4(analogy to the mammalian apoptotic protease activating factor 1, 
Apaf-1),  leading to the activity of ced- 3/ ced- 4 complex which is controlled by apoptosis 
inhibitor ced- 9 as well as apoptosis inducer egl- 1.ced- 9 and egl- 1 are members of the Bcl-2 
family of pro- or antiapoptotic proteins (Richardson, 2002). 
1.5.3.1  Caspases: 
                 The name caspases is an acronym for cysteine – dependent  aspartate- specific 
protease; their catalytical action depends upon a crucial cysteine residue inside a highly 
conserved pentapeptide sequence QACRG active site, and the caspases distinctively split their 
cellular substrate after Aspartic acid residues. They function by attacking cytoskeletal as well 
as nuclear proteins important for retaining cell architecture, and enzymes entailed in 
metabolism and repair. Hitherto 7 different caspases have been discovered in Drosophila, and 
14 different members have been defined in mammals. Additionally caspase -11  and caspase -
12 solely identified in the mouse(Gorman et al., 1998; Denault, 2002; Richardson, 2002).     
Based on its function, caspases have been categorized into two groups: upstream, apical or 
initiator caspases such as -2, -8,  -9 and -10, and downstream, effector or executioner such as 
caspases -3, -6, and -7(Ashkenazi and Dixit, 1998; Nicholson, 1999). Caspases are synthesized 
as inactive pro-enzymes whose activation is  set off through vast array of internal and external 
stimuli(reviewed in Li and Yuan, 2008). It wasn’t until receipt apoptotic stimuli, cells energize 
and activate apical caspases which in turn and in  proteolytic cascade cleave and actuate the 
executioner caspases. After becoming active, executioner caspases proteolytically split a 
variety of substrate resulting in the destruction of dying cell( Fischer et al., 2003). Structurally, 
active caspases have a highly conserved homodimeric structure stemming from the 
combination of two identical  monomer catalytic domains. Each catalytic domain comprising 
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of one active site that is contains one large(20 k Da) as well as one small(10 k Da) domains. 
Upon maturation, pro-caspases(latent zymogens) are proteolytically processed at the cleavage 
site positioned between the large and the small domains. During caspase activation, both the 
small and large subunits assemble, forming a heterodimer with both subunits contributing 
important residues for substrate binding and catalytic activities as well (Nicholson and 
Thornberry, 1997; Gupta, 2000). Furthermore, the apical caspases are distinguished by long 
pro-subunit that act as platform for recruiting activated adaptor proteins. The pro-domain of 
both caspase -2 and 9 possess a caspase recruitment domain(CARD),compared to caspase -8 
and -10 embody two tandem repeats of the death effector domain(DED). In each case, these 
subunits interact homotypically with adaptors that promote caspase activation via a 
mechanism of introduced propinquity, wherein the close juxtaposition of two caspases results 
in the formation of an active caspase tetramer. Activation and initiation of caspases may 
transpire through either an extrinsic or an intrinsic pathway(reviewed in Danial and 
Korsmeyer, 2004).  
                    Intrinsic pathways are initiated by procaspase-9 which is triggered downstream of 
mitochondrial proapoptotic events at apoptosome, a cytosolic death signaling protein complex 
that is formed on the release of cytochrome c from mitochondria. In that event, procaspase-9 
molecule dimerizes at the Apaf-1 scaffold that triggers the activation of caspase -9(Salvesen 
and Renatus  , 2002b; Denault, 2002). Once the apical caspases have been triggered, they 
proteolytically and hierarchically activate the executioner procaspase-3, -6 and -7 which 
subsequently cleave a specific set of protein substrates, including pro-caspases themselves, 
leading to the mediation and amplification of the death cue and finally  in the execution of cell 
death with all the morphological and biochemical characteristics  usually observed [Earnshaw, 
1999]. 
                  Extrinsic pathways are directed by procaspase-8 that is recruited by its DED to the 
death inducing signaling complex(DISC), a membrane receptor complex formed consequently 
the ligation of the tumor necrosis factor receptor(TNFR) family. Once bound to DISC, several 
pro-caspase-8 molecules are in close proximity to each other and are assumed to activate each 
other accordingly via autoproteolysis(Sartorius et al., 2001; Denault, 2002).    
1.5.3.2  Intrinsic pathway: 
            DNA damage inevitably,  result in either upregulation of Bax or downregulation of 
Bcl-2 that subsequently permeabilize the mitochondria to liberate pro-apoptotic factors for 
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instance cytochrome c, a well-known trigger of pro-caspase-9 activation, ensuing by 
downstream apoptotic effectors(Crompton, 2000). Nonetheless, it has been proved that in 
response to DNA damage, activation of caspase-2 is prerequisite ahead mitochondria 
permeabilization and release of cytochrome-c(Guo et al., 2002; Lassus et al., 2002; 
Vakifahmetoglu et al., 2006). After freeing cytochrome-c, it attaches to apoptotic protease 
activating factor Apaf-1 forming apoptosome( multi protein complex), in nucleotide 
dATP/ATP dependent manner(Zou et al., 1999). Afterward the apoptosome recruits pro-
caspase-9 forming an active holoenzyme, that additionally activates downstream effector 
caspases namely caspase-3 and -7 and then results in programmed cell death(Jiang and Wang, 
2004).   
 
 
 
 
 
 
2- Rationale and specific aims: 
                Folate bioavailability could paradoxically  influence the response of cells to UV-
light exposure, as well as to anti-folate cancer drugs, both in terms of inhibiting proliferation, 
and in terms of prolonging cell survival (escape from apoptosis). Folate depletion could result 
in uracil misincorporation, that could activate onco- protein such as c-Myc which augur bad 
for carcinogenesis. While excessive  folate administration not only may reinvigorate and 
revive cells, but also may adversely act against treatment. Fortunately c-Myc activity can be 
abolished by using antic-Myc 10058-F4. However this might affect normal cells that express 
small amount of this protein Intriguingly it has been published that, SHMT can bypass the 
effect of c-Myc. Furthermore, cSHMT catalyzes the hydrolysis of 5,10 methenyl THF to 
folinic acid which is canonical in reversing the effects of antifolate drugs, additionally, the 
chemopreventive function of folic acid which 100 time less stronger than folinic acid maybe 
linked to its capacity to down-regulate IGF-1R level. Accordingly we would like to use folinic 
acid hoping that it might mimic the role played by SHMT.   
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               The present project is aimed to use a human pro-myelocytic cell line (HL-60) and 
PHA-activated human Lymphocytes to test the effect of folates (folinic acid) on the response 
to UV-light, serum free medium, presence of growth factor and anti c-Myc 
               Different doses of folates and UV exposure will be tested and relative kinetics of 
proliferation and apoptosis will be recorded. The distribution of cells in the cell cycle phases 
will be monitored by PI incorporation and flow cytometry analysis. 
 
 
 
 
 
 
 
 
3.  Methodology and Results 
3.1 Cell culture: 
                The established cell line of transformed human promyelocyte leukemic cell line ( 
HL- 60), a kind gift from Dr Paola Secchiero from (Human anatomy unit, university of 
Ferrara),it is round mononuclear cell, with microvilli. Moreover,  it is well known that HL-60 
was found rapidly undergoes apoptosis after a short periods of UV exposure(Martin and 
Cotter, 1991), was routinely cultured in Iscove’s Modified Dulbecco's Medium( Gibco Life 
technologies),  supplemented with 5% fetal bovine serum( Gibco Life technologies), and kept 
at 37° C in an atmosphere of 95% air and 5% CO2. 
3.2 Irradiation of cells with UVC light: 
                Prior to treatment with UVC, cells were maintained in  serum starved Iscove 
medium , then plated in six petri dishes(Becton Dickinson USA), at density 4x10
6
/4ml for 
each. Next day each plate was placed uncovered in UV stratalinker(stratagene model 1800: 8 
watts each) under a UV bulb emitting chiefly 254-nm for different time 0(untreated), 0.1, 0.5, 
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1, 5, and 10 minutes. Then incubated  at 37° C in an atmosphere of 95% air and 5% CO2 for 2 
hours. After that cells were harvested(day 0) and the plate supplemented with 500 µl fetal 
bovine serum. Then cells were harvested after 1, 2, 3, 6 and 7 days whereby cell count and cell 
viability as well were checked using haemocytometer and trypan blue dye exclusion. 
3.3 Trypan Blue dye Exclusion: 
                10μl of the cell suspension was then added to10μl of trypan blue(Sigma, Dorset, 
UK)).10μl of this mix were aliquoted and loaded into the haemocytometer. To assess the 
concentration of HL-60 and  PBMCs, the live cells (white cells) were counted in two diagonal 
quadrants in both sides and divided by 105 to give the number of cells per ml of cell 
suspension. The number of blue cells (dead cells) was also counted in two diagonal quadrants. 
The % viability was calculated by the following equation: 
 
Viability % =  
3.2.1 Results: 
             Not surprisingly, cells thrive, flourish and proliferate in presence of fetal bovine serum 
since its rich in growth factor(p>0.05). Accordingly, UVC untreated cells have nearly 
quadruple its number by day 3,  and after that its number steadily  began to level off and 
decline. meanwhile cells that have been  treated for short dose undergo transient arrest as it 
had halted proliferating for a while then re-entered cell cycle and restore back its proliferative 
capacity by day 6, no significant difference between UVC untreated cells and that treated with 
short dose(p<0.05). Whereas cells that subjected to a relatively short  and high doses of UVC 
have resulted in initial cell cycle arrest hence cells  nimbly underwent apoptosis en masse as 
no much difference between two doses(p<0.05)  depicted in table and figure 
Table 3.1  shows – UVC induced apoptosis (cell proliferation) using haemocytometer: 
time 0 1 2 3 6 7 
0 min 1.565 1.97 2.595 4.125 3.525 0.2115 
0.1 min 1.545 0.725 0.46 0.36 1.085 2.17 
0.5 min 1.525 0.68 0.255 0.1 0.02 0 
1 min 1.45 0.57 0.135 0.05 0.005 0 
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5 min 0.83 0.2 0.015 0.01 0 0 
10 min 0.29 0.015 0.0125 0.005 0 0 
 
       
Figure 3.1  shows UVC induced apoptosis (cell proliferation) using haemocytometer: 
 
Table 3.2   shows UVC induced apoptosis (cell survival) using haemocytometer:  
time 0 1 2 3 6 7 
0 min 82 87 88.1 94 72 41.9 
0.1 min 77 44 23.5 14 30.7 52.2 
0.5 min 71.1 33.4 12 4.3 0.77 0.0 
1 min 69 26.5 6.7 2.2 0,27 0.0 
5 min 61.9 13.8 0.97 0.5 0.0 0.0 
10 min 28.5 0.9 0.4 0.4 0.0 0.0 
 
 
 47 
 
       
Figure 3.2   shows UVC induced apoptosis (cell survival) using haemocytometer: 
3.4 Effect of Folinic acid on cell proliferation and apoptosis in UV-C treated HL60 cells: 
              To study the  effect of Folinic acid on cell proliferation and apoptosis in UV-C treated 
HL60 cells, therefore  before treating cells  with UVC, serum was eliminated , and cells were  
washed twice in PBS, then resuspended and seeded in Iscove’s modified Dulbecco’s serum 
free medium, plated in different dishes at concentration of 1x10
6
cells/ ml and incubated 
overnight. Next day supplemented with increasing doses of 5- formyltetrahydrofolate(Sigma)  
in a dose- dependent manner namely 0, 10, 25, 100 and 400 µg/ml respectively,  and then 
placed uncovered in UV stratalinker( stratagene model 1800: 8 watts each) under a UV bulb 
emitting chiefly 254-nm. Cells subjected to escalating single dose of UVC radiation namely 0 
minute, 0.5 minute and 10 minutes. Cells were harvested after 2h, 2 and 6 days, where both 
cell count and cell viability were performed. 
3.4.1 Results: 
           In the present study folinic acid used to reverse the cytotoxic effect that, induced by 
UVC, the results show that, regarding UVC untreated cells, folinic acid induce cell 
proliferation in absence of growth factors by certain point then cell numbers spontaneously 
began declining to fall behind  the baseline by day 6. The voluminous proliferation in a dose 
dependent manner. Folinic acid has a minimal effect against cytotoxicity induced by 
UVC(p˂0.05),  as cells that subjected for relatively short and long doses underwent apoptosis 
en masse  by day 6. Supplementing cells with supraphysiologic dose(400 µg/ml) of folinic 
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acid which statistically significant in sustaining and rescuing cells a bit, but it hasn’t  far 
enough enabling cells to restore its proliferation potentiality(p˂0.05),   as described in table 
and figure 
Table 3.3   shows UVC untreated cells and folinic acid doses( cell proliferation) 
 
 
 
 
 
 
 
 
 
 
5-FTHF 0 2 6 
0 µg/ml 1.585 1.775 0.64 
10 µg/ml 1.43 1.89 1.025 
25 µg/ml 1.86 2.695 0.69 
100 µg/ml 1.345 2.06 0.63 
400 µg/ml 1.545 2.98 3.025 
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Figure 3.3 shows UVC untreated cells and folinic acid doses( cell proliferation) 
 
 Table 3.4 UVC untreated cells survival using trypan blue dye exclusion: 
 
 
 
 
 
 
 
5-FTHF 0 2 6 
0 µg/ml 0.9 0.82 0.19 
10 µg/ml 0.925 0.87 0.27 
25 µg/ml 0.93 0.86 0.19 
100 µg/ml 0.94 0.9 0.2 
400 µg/ml 0.93 0.91 0.56 
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Figure 3.4  Table UVC untreated cells survival using trypan blue dye exclusion:  
 
 
Table 3.5 shows UVC treated cells with 0.5 minute cell proliferation: 
 
 
 
 
 
 
 
5-FTHF 0 2 6 
0 µg/ml 1.05 0.01 0 
10 µg/ml 1.22 0.015 0 
25 µg/ml 1.34 0.02 0 
100 µg/ml 1.44 0.04 0 
400 µg/ml 1.285 0.155 0.01 
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Figure 3.5 shows  UVC treated cells with 0.5 minute cell proliferation 
 
Table  3.6  demonstrates Cells treated with UVC for 0.5 minute (cell survival) using 
trypan blue exclusion: 
 
 
 
 
 
 
 
5-FTHF 0 2 6 
0 µg/ml 0.4 0.004 0 
10 µg/ml 0.512 0.006 0 
25 µg/ml 0.48 0.009 0 
100 µg/ml 0.45 0.02 0 
400 µg/ml 0.45 0.073 0.004 
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Figure 3.6  Cells treated with UVC for 0.5 minute (cell survival) using trypan blue 
exclusion 
 
 
Table 3.7  illustrates Cells treated with UVC for 10 minutes( cell proliferation): 
 
 
 
 
5FTHF 0 2 6 
0 µg/ml 0.165 0 0 
10 µg/ml 0.32 0.01 0 
25 µg/ml 0.75 0.015 0 
100 µg/ml 0.11 0.02 0 
400 µg/ml 0.92 0.05 0.005 
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Figure 3.7 shows  Cells treated with UVC for 10 minutes( cell proliferation): 
3.4.2  Effect of Folinic acid on cell proliferation and apoptosis in UVC treated HL-60 
cells 
                  Cells were starved in Iscove serum free medium overnight. Next day supplemented 
with increasing doses of folinic acid namely 0, 100 and 400 µg/ml. thereafter exposed to 
different doses of  UVC specifically,  0.1 minute and 0.5 minute. Additionally we use UVC 
untreated cells as control. Cells were harvested after 2hour, 3, 4 and 6 days post-radiation 
where cell count and viability were performed.   
3.4.2.1 Result: 
            Concerning UVC untreated cells folinic acid induced exponential proliferation that 
culminates by day 3, and then cells began levelling off its number. Whereas in UVC treated 
cells folinic acid significantly( p>0.05),  sustains cells  survival and viability as much as 6 days 
as in our case. But doesn’t go far enough in restoring back the machinery of cell proliferation 
as illustrated in table 3.8 and figure 3.8.  
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Table 3.8 shows  UVC untreated cell (cell proliferation) using haemocytometer: 
5FHTF 0 3 4 6 
 0 µg/ml 0.805 0.815 0.72 0.401 
100 µg/ml 0.75 1.165 1.005 0.815 
400 µg/ml 0.815 1.355 1.22 1.245 
 
      
Figure 3.8  illustrates UVC untreated cell (cell proliferation) using haemocytometer 
Table 3.9 shows UVC untreated cell (cell survival) using trypan blue dye exclusion: 
5FHTF 0 3 4 6 
 0 µg/ml 0.8 0.608 0.54 0.22 
100 µg/ml 0.9 0.789 0.69 0.406 
400 µg/ml 0.89 0.797 0.664 0.526                                   
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Figure 3.9  shows UVC untreated cell (cell survival) using trypan blue exclusion 
Table 3.10 demonstrates Cells treated with 0.1 minute UVC cell proliferation using 
haemocytometer 
5FTHF 0 3 4 6 
0 µg/ml 0.685 0.02 0 0 
100 µg/ml 0.8 0.075 0.1 0.02 
400 µg/ml 0.7 0.14 0.115 0.035 
 
 
      
Figure 3.10 demonstrates Cells treated with 0.1 minute UVC cell proliferation using 
haemocytometer 
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Table 3.11 shows % Cells treated  with 0.1 minute UVC (cell survival) using trypan blue 
exclusion: 
5FTHF 0 3 4 6 
0 µg/ml 0.67 0.0143 0 0 
100 µg/ml 0.75 0.04 0.063 0 
400 µg/ml 0.84 0.107 0.086 0.027 
 
      
Figure 3.11 shows % Cells treated  with 0.1 minute UVC (cell survival) using trypan blue 
exclusion: 
 
Table 3.12 UVC treated cells for 0.5 minutes cell count using haemocytometer: 
5FTHF 0 3 4 6 
0 µg/ml 0.62 0 0 0 
100 µg/ml 0.67 0.005 0.005 0 
400 µg/ml 0.55 0.015 0.01 0.005 
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Figure 3.12 UVC treated cells for 0.5 minutes cell count using haemocytometer 
Table 3.13  UVC treated cells for 0.5 minutes cell viability using trypan blue dye 
exclusion 
5FTHF 0 3 4 6 
0 µg/ml 0.558 0 0 0 
100 µg/ml 0.65 0.004 0.004 0 
400 µg/ml 0.58 0.0106 0.007 0.0029 
 
      
Figure 3.13 UVC treated cells for 0.5 minutes cell viability using trypan blue dye exclusion   
3.4.3 Effects of pre and post- treatment and UVC on cell proliferation 
               One group of Cells were serum- starved in Iscove medium overnight. Next day 
supplemented with different doses of folinic acid namely 0, 100 and 400 µg/ml and 
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immediately after that exposed to UVC light for 0.5 minute. While the other group starved 
overnight, exposed to UVC light then latter supplemented with same doses of folinic acid. 
Cells were harvested after 2h, 3, 4, and 6 day post- radiation. 
3.4.3.1 Result: 
           In reality no remarkable differences between pre and post folinic acid treatment. Since 
both groups underwent apoptosis en masse after exposing to relatively short doses of UVC. 
furthermore,  there no significant  difference between pre and  post- treatment(p˂0.05). as 
depicted in table and figure 
Table 3.14 Effects of post treatment of folinic acid and UVC on cell proliferation 
5FTHF 0 3 4 6 
0µg/ml 0.955 0 0 0 
100 µg/ml 1.165 0.01 0.005 0 
4oo µg/ml 1.215 0.025 0.01 0 
 
       
Figure 3.14 Effects of post-treatment of folinic acid and UVC on cell proliferation 
 
 59 
 
 
 
Table 3.15 Effects of post-treatment of folinic acid and UVC on cell survival 
5FTHF 0 3 4 6 
0µg/ml 0.547 0 0 0 
100 µg/ml 0.677 0.0061 0.003 0 
4oo µg/ml 0.764 0.015 0.0057 0 
 
     
Figure 3.15 Effects of post-treatment of folinic acid and UVC on cell survival 
Table 3.16  Effect of pre-treatment of folinic acid and UVC on cell proliferation 
5FTHF 0 3 4 6 
0µg/ml 0.985 0 0 0 
100 µg/ml 1.4 0.005 0 0 
400 µg/ml 1.015 0.01 0.005 0 
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Figure 3.16  Effect of pre-treatment of folinic acid and UVC on cell proliferation       
 
Table 3.17  Effects of pre-treatment of folinic acid and UVC on cell viability 
5FTHF 0 3 4 6 
0µg/ml 0.586 0 0 0 
100 µg/ml 0.729 0.0027 0 0 
4oo µg/ml 0.76 0.0062 0.0026 0 
 
       
Figure 3.17 Effects of pre-treatment of folinic acid and UVC on cell viability 
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3.5 Irradiation of cells with UVB light: 
                 cells were exposed to UVB (dose 72 J/cm2, wavelength 312 nm, Transilluminator 
UV gene
TM
, Bio- Rad laboratories, Hercules USA in a dose- dependent manner for three 
different times namely, 0 minute, 1 minute and 10 minutes at room temperature, at I cm 
distance. 
3.5.1 Effects of UVB and folinic acid on cell proliferation and apoptosis: 
                Cells were starved overnight in Iscove serum free medium. Next day before the 
culture being prepared, cell count and cell viability were checked. Thereafter 5x 10
6
/ 5ml of 
cells were being aliquoted in(35x 100 mm) dishes. Then supplemented with/no two different 
doses of folinic acid namely 0, 100 and 400 µg/ml, after that exposed to different doses of 
UVB namely for I minute and 10 minutes, in addition to control cells. Cells were harvested 
after 2h, 3, 4 and 6 day post- irradiation where cell count and cell viability were performed. 
3.5.1.1 Result: 
           Folinic acid is instrumental in inducing exponential cell proliferation as seen in case of  
UVB untreated cell. Cells  steadily replicate and doubled its number that reached its peak  by 
day 3, then started dwindling. Needless to say , cell proliferation and cell survival as well are 
nearly  dose dependence(p>0.05). In reference to UVB cells that, treated for short period 
(1minute), there are inconspicuous decrease in cell number compared to UVB untreated cells. 
With regard to UVB cells that relatively, treated high dose( 10 minutes), Folinic acid deficient 
cells underwent apoptosis en masse and  vanished by day3, whereas folinic acid supplemental 
cell levelled off and underwent apoptosis by day 6 . the dose at 100 µg/ml was found to protect 
Hl-60 after I minutes 
Table 3.18 Effects  of folinic acid on proliferation of untreated cells 
5FTHF              0  3  4  6 
0µg/ml 1.55 2.13 1.93 1.275 
100 µg/ml 1.49 2.555 2.04 1.625 
400 µg/ml 1.25 2.455 2.01 1.71 
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Figure 3.18 Effects  of folinic acid on proliferation of untreated cells 
 
 
Table 3.19 Effects of folinic acid on cell survival of untreated cells 
5FTHF 0 3 4 6 
0µg/ml 0.85 0.733 0.57 0.38 
100 µg/ml 0.88 0.825 0.67 0.412 
400 µg/ml 0.92 0.85 0.702 0.412 
 
  
Figure 3.19 Effects of folinic acid on cell survival of untreated cells  
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Table 3.20 Effect of UVB and folinic acid on cell proliferation with 1 minute UVB 
exposure 
5FTHF  0  3  4  6 
0µg/ml 1.4 1.025 0.78 0.256 
100 µg/ml 1.48 1.61 1.35 0.39 
400 µg/ml 1.54 1.52 1.085 0.275 
 
     
Figure 3.20  Effect of UVB and folinic acid on cell proliferation with 1 minute UVB 
exposure 
Table 3.21 Effects of UVB and folinic acid on cell survival with 1 minute UVB exposure 
5FTHF 0 3 4 6 
0µg/ml 0.8 0.48 0.25 0.068 
100 µg/ml 0.82 0.62 0.463 0.123 
400 µg/ml 0.846 0.62 0.432 0.094 
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Figure 3.21 Effects of UVB and folinic acid on cell survival with 1 minute UVB exposure 
 Table 3.22 Effects of UVB and folinic acid on cell proliferation with 10 minute UVB 
exposure 
5FTHF  0  3  4  6 
0 µg/ml 1.3 0 0 0 
100 µg/ml 1.4 0.005 0.005 0 
400 µg/ml 1.44 0.015 0.01 0 
 
     
Figure 3.22 Effects of UVB and folinic acid on cell proliferation with 10 minute UVB 
exposure   
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Table 3.23 Effects of UVB and folinic acid on cell survival with 10 minutes UVB 
exposure 
5FTHF 0 3 4 6 
0µg/ml 0.726 0 0 0 
100 µg/ml 0.81 0.002 0.002 0 
400 µg/ml 0.847 0.008 0.005 0 
 
 
     
 Figure 3.23  Effects of UVB and folinic acid on cell survival with 10 minutes UVB exposure    
3.5.2 5FTHF doses on UVB-treated HL-60 cells 
           to determine which is the 5FTHF dose that prevents apoptosis after 1 min UV-B 
exposure. Cells were starved overnight in Iscove serum free medium. Next day before the 
culture being prepared both cell count and viability were checked. Then cells plated at 5x10
6
 
cells in 5 ml(6x35 mm)Iscove serum free medium. Then different doses of folinic acid were 
added namely 0, 5, 10, 25, 50 and 100 µg/ml. then plates were exposed to UVB for 1 minute. 
Cells harvested at 2h and 3 days post- radiation where cell count and viability were checked. 
3.5.2.1 Result: 
           Folinic acid seems to reinvigorate cells against toxicity such as UVB light. Apart from 
folinic acid restriction cell, all folinic acid supplemental cell continued proliferating 
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proportionately with varying degrees or directly proportional to folinic acid concentration. 
Supraphysiologic dose 100 µg/ml is impeccably perfect for inducing proliferation since cells 
nearly double its number as shown in table and figure 
Table 3.24 cell proliferation using haemocytometer: 
5FTHF  0  3 
0 µg/ml 1.035 0.97 
5 µg/ml 0.86 1.6 
10 µg/ml 1.07 1.615 
25 µg/ml 1.295 1.735 
50 µg/ml 1.265 1.7 
100 µg/ml 1.2225 1.86 
 
               \ 
Figure 3.24 cell proliferation using haemocytometer 
Table 3.25 Cell survival using trypan blue exclusion 
5FTHF 0 3 
0 µg/ml 0.73 0.42 
5 µg/ml 0.77 0.53 
10 µg/ml 0.8 0.56 
25 µg/ml 0.88 0.61 
50 µg/ml 0.89 0.64 
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100 µg/ml 0.85 0.72 
 
                  
Figure 3.25 Cell survival using trypan blue dye exclusion 
3.5.3 UVB dose exposure of HL-60 cells treated with 5FTHF ( cell count) 
               Cells were starved overnight and maintained in Iscove serum free medium, thereafter 
plated into six dishes(5x10
6
/5ml) for each. Next day supplemented with 100 µg/ml, then 
exposed to different doses of UVB(312 nm) namely, 0, 0.5, 1, 2, 5, 10 minutes respectively. 
Cells harvested after 2h and 3 days post- irradiation treatment, where both cell count and 
viability were done. 
3.5.3.1 Result: 
           Folinic acid tremendously, bolster up and sustain cellular proliferation. Nevertheless it 
is functioning well with low- doses of UVB specifically with 0.5 and 1 minute UVB as found 
out in the present study. With regard to relatively low- dose and high- dose as well, 
supraphysiologic dose fails to keep cells safe and sound, instead cells underwent apoptosis en 
masse   
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Table 3.26 cell proliferation using haemocytometer 
time 0 3 
0 min 1.085 1.63 
0.5 min 1.03 1.12 
1 min 1.03 1.45 
2 min 0.975 0.045 
5 min 0.925 0.02 
10 min 0.905 0.015 
 
                           
 
Figure 3.26 cell proliferation using haemocytometer 
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Table 3.27 % Cell survival using trypan blue dye exclusion: 
time 0 3 
0 min 0.86 0.64 
0.5 min 0.84 0.54 
1 min 0.8 0.52 
2 min 0.72 0.02 
5 min 0.68 0.009 
10 min 0.62 0.007 
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Figure 3.27 Cell survival using trypan blue dye exclusion: 
     
3.5.4 UVB dose exposure of HL-60 cells treated with 5FTHF ( cell count) 
               to determine which is the maximum UV-B exposure for which 5FTHF (100ug/ml) 
prevents apoptosis, thereby cells were starved overnight and maintained in Iscove serum free 
medium, thereafter plated into six dishes(5x10
6
/5ml) for each. Next day supplemented with 
100 µg/ml, then exposed to different doses of UVB(312 nm) namely, 0, 0.5, 1, 2, 5, 10 
minutes respectively. Cells harvested after 2h and 3 days post- irradiation treatment, where 
both cell count and viability were done, and cell fixed with formaldehyde(     ), permeabilized 
with cold methyl alcohol and analysed using flow cytometry.  
3.6 Cell cycle protocol with propidium iodide PI: 
                   Cells(2x10
6
/2ml) were harvested, and washed in 1x phosphate buffered saline( 
PBS) at 1200 rpm for 3 minutes. then supernatant was discarded, and pellet was resuspended 
in 2 ml of 1x PBS. 6 ml of formaldehyde were added dropwise while vortexing, and incubated 
at room temperature for 10 minutes. then centrifuged at 1200 rpm for 5 minutes. Cells were 
permeabilized with cold absolute methyl alcohol solution for at least 1 hour at - 20°C. Then 
cells were washed twice in 1x PBS at 1200 rpm for 5 minutes. Supernatant was discarded and 
cells were resuspended in PI at final concentration 50 µg/ml (a combination of  450µl PBS and 
25µl of propidium iodide) for 30 minutes on ice. Then cells were washed twice in 1x PBS at 
1200 rpm for 5 minutes. The supernatant was discarded the pellet was resuspended in 300 µl 
of 1x  PBS. Then the DNA content was analysed by using cytometer( FACScan flow 
cytometer; Becton Dickinson, San Jose, CA) at an excitation wavelength of 488 nm. The data 
were analysed using the software program( Cell Quest, Becton Dickinson). 
3.5.4.1 Result: 
               Folinic acid nicely enable and further untreated cells to proliferate thrice by day 3 as 
well as  cells that  treated with low doses of UVB(0.5 min and 1 min) appears. Intriguingly,  
UVB treated cells that treated with relatively low dose(2 minute), more likely,  there is initial 
hiatus of cell cycle  and therefore cells underwent apoptosis en masse. The same phenomenon 
observed in UVB treated  cells which exposed to high doses (5 and 10 min). UVB dose for 2 
minutes  is a potent and  killing dose, mount same effects of high doses( 5 & 10) min, as cells 
underwent apoptosis. During cell proliferation the  flow cytometric analysis shows that, 
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increasing number of cells in the S and G2/M phases and decreasing  number of cells   in sub 
G1phase which is evident in UVB untreated cells and UVB treated with low doses. Whereas 
in UVB treated with relatively and high doses there are low  percentage in S and G2/M phase 
and high cell percentage in sub G1 cells.   
 
  
Table 3.28 UVB dose exposure HL-60 supplemented with 5FTHF (cell count) using 
haemocytometer 
time 0 3 
0 min 1.69 3.685 
0.5 min 1.59 3.27 
1 min 2 3.17 
2 min 1.46 0.09 
5 min 1.45 0.045 
10 min 1.165 0.025 
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Figure 3.28 UVB dose exposure HL-60 supplemented with 5FTHF (cell count) using 
haemocytometer   
 
 
 
 
Table 3.29 % UVB dose exposure HL-60 supplemented with 5FTHF (cell survival) using 
Trypan blue dye exclusion 
time 0 3 
0 min 0.938 0.9 
0.5 min 0.913 0.847 
1 min 0.889 0.828 
2 min 0.848 0.027 
5 min 0.798 0.0157 
10 min 0.685 0.0068 
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Figure 3.29  % UVB dose exposure HL-60 supplemented with 5FTHF (cell survival) using 
Trypan blue dye exclusion   
 
 
3.6.1 Flow cytometric analysis     
3.6.1.1  control  proliferating cell day 1 
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3.6.1.2  control proliferating cell day 3  
 
 
3.6.1.3  0 UVB  exposure – 100 µg/ml  5FTHF day 0 
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3.6.1.4  0  UVB  exposure – 100 µg/ml  5FTHF day 3 
 
 
3.6.1.5  0.5 minutes UVB exposure, 100 µg/ml 5FTHF- day 0 
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3.6.1.6  0.5 minute UVB exposure, 100 µg/ml 5FTHF- day 3 
 
 
 
 
3.6.1.7  1 minute UVB exposure, 100 µg/ml 5FTHF- day 0 
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3.6.1.8  1 minute UVB exposure, 100 µg/ml 5FTHF- day 3 
 
 
 
 
 
 
3.6.1.9 2 minute UVB exposure, 100 µg/ml 5FTHF- day 0 
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3.6.1.10 2 minute UVB exposure, 100 µg/ml 5FTHF- day 3 
 
 
 
 
3.6.1.11 5 minute UVB exposure, 100 µg/ml 5FTHF- day 0 
 
 
 79 
 
3.6.1.12 5 minute UVB exposure, 100 µg/ml 5FTHF- day 3 
 
 
3.6.1.13 10 minute UVB exposure, 100 µg/ml 5FTHF- day 0 
 
 
3.6.1.14 10 minute UVB exposure, 100 µg/ml 5FTHF- day 3 
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3.6.1.15 Overlay day 0 
    
 
3.6.1.16 Overlay day 3 
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3.5.5 5FTHF doses on UVB treated HL-60 
            to determine which is the 5FTHF dose that might prevent apoptosis after 1 min UV-B 
exposure. Therefore,  cells were starved and maintained overnight  in Iscove serum free 
medium. Then plated in 8 dishes Next day. increasing concentrations( 0,1.25, 2.5,  5, 10,25, 50 
and 100 µg/ ml) of folinic acid were added to each plate, then all dishes were exposed to UVB 
for 1 minute using transilluminator UV gene 
TM
, then cells were harvested, cell count using 
haemocytometer, cell viability using trypan blue dye exclusion and flow cytometry using 
propidium iodide(PI) were performed. 
3.5.5.1 Results: 
             Folinic acid strongly support cell proliferation, in this context folinic acid deficient 
cells failed to proliferate and underwent cell cycle arrest and subsequently,  apoptosis en 
masse by day 3. Whereas the folinic acid supplemental cells had proliferated and increased 
their number proportionately more according to increasing folinic doses as well evident in 
cells supplemented with relatively high doses(25,50 and 100 µg/ml) of folinic acid managed to 
double their number. The flow cytometric analysis reveals that high doses promote 
proliferation as there is high percentage of cells in S and G2/M phases, and low percentage of 
cells in sub G1.   
 
 
 
 
 
1.  Table 3.30 shows 5FTHF doses on UVB treated HL-60 cell (cell proliferation) 
by Haemocytometer: 
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5FTHF 0 3 
0 µg/ml 1.285 0.695 
1.25 µg/ml 1.1 0.685 
2.5 µg/ml 1.125 0.685 
5 µg/ml 1.235 0.725 
10 µg/ml 1.22 1.45 
25 µg/ml 1.35 1.99 
50 µg/ml 1.42 2.24 
100 µg/ml 1.45 2.67 
 
            
Figure 3.30 shows 5FTHF doses on UVB treated HL-60 cell (cell proliferation) by 
Haemocytometer: 
2. Table  3.31 shows 5FTHF doses on UVB treated HL-60 cell (cell survival) by 
(% of Trypan blue dye exclusion): 
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5FTHF 0 3 
0 µg/ml 0.892 0.262 
1.25 µg/ml 0.905 0.314 
2.5 µg/ml 0.929 0.293 
5 µg/ml 0.925 0.348 
10 µg/ml 0.917 0.481 
25 µg/ml 0.945 0.742 
50 µg/ml 0.965 0.78 
100 µg/ml 0.97 0.78 
 
            
Figure 3.31 shows 5FTHF doses on UVB treated HL-60 cell (cell survival) by (% of Trypan 
blue dye exclusion): 
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3.5.5.2 PI of stained cells by FACS:  
3.5.5.2.1 Control: proliferating cells (no UVB exposure) 
 
 
 
3.5.5.2.2  min UVB exposure;  0 µg/ml 5FTHF;  day0 
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3.5.5.2.3 1 min UVB exposure; 0 µg/ml 5FTHF; day3 
 
 
 
3.5.5.2.4 Overlay: 
 
3.5.5.2.5 1 min UVB exposure; 1.25 µg/ml 5FTHF; day0 
 
 
 
 86 
 
 
 
 
3.5.5.2.5 1 min UVB exposure; 1.25 µg/ml 5FTHF; day3 
 
 
3.5.5.2.7 Overlay: 
 
3.5.5.2.8 1 min UVB exposure; 2.5 µg/ml 5FTHF; day0 
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3.5.5.2.9 1 min UVB exposure; 2.5 µg/ml 5FTHF; day3 
 
 
 
3.5.5.2.10 Overlay: 
 
3.5.5.2.11 1 min UVB exposure; 5 µg/ml 5FTHF; day0 
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3.5.5.2.12 1 min UVB exposure; 5 µg/ml 5FTHF; day3 
 
 
 
 
3.5.5.2.13 Overlay: 
 
3.5.5.2.14 1 min UVB exposure; 10 µg/ml 5FTHF; day0 
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3.5.5.2.15 1 min UVB exposure; 10 µg/ml 5FTHF; day3 
 
 
3.5.5.2.16 Overlay: 
 
 
3.5.5.2.17 1 min UVB exposure; 25 µg/ml 5FTHF; day0 
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3.5.5.2.18 1 min UVB exposure; 25 µg/ml 5FTHF; day3 
 
 
 
3.5.5.2.19 Overlay: 
 
 
3.5.5.2.20 1 min UVB exposure; 50 µg/ml 5FTHF; day0 
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3.5.5.2.21 1 min UVB exposure; 50 µg/ml 5FTHF; day3 
 
 
 
3.5.5.2.22 Overlay: 
              
 
3.5.5.2.23  1 min UVB exposure; 100 µg/ml 5FTHF; day0 
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3.5.5.2.24 1 min UVB exposure; 100 µg/ml 5FTHF; day3 
    
         
   
  3.5.5.2.25 Overlay: 
 
3.5.6 5FTHF doses on UVB-treated HL-60 cells :  
              To describe the time course of apoptosis in starved HL-60 cells, and depending on 
5FTHF doses.  Cells were washed twice in 1x PBS, and after being  starved by seeding for two 
consecutive days in Iscove serum free medium,  cells were supplemented with/no increasing 
doses of folinic acid in a dose- dependent manner namely 0, 5, 10, 25 and 50 µg/ml and 
incubated at 37° C in an atmosphere of 95% air and 5% CO2. Afterwards cells were exposed 
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to UVB for 1 minute and then incubated. One day latter  cells were harvested after 1,2, 3 and 6 
days where cell count , viability and PI were performed. 
3.5.6.1 Result: 
           Concerning  the cell that has maintained in serum free medium and 5FTHF deficient 
there is a transient arrest of replication by 24 h post-irradiation as evidenced by reduction in 
cell number, then one day latter  the cell re-entering the cell cycle by 48 h post- radiation then 
levelled off by day 3. Folinic acid was crucial and remarkable in promoting cells proliferation 
and rescuing cells from apoptosis(p>0.05). The results confirmed latter by flow cytometric 
analysis which shows increase in phase S and G2/M2 cells  With regard to cells that   grown in 
Iscove serum free media which supplemented with  5FTHF continued proliferating in dose- 
dependent manner, and  levelled off by day 3. The flow cytometric analysis show increase in 
subG1 cell and decrease in S and G2/M cells respectively.   
 
 
 
 
Table 3.32 shows 5FTHF doses on UVB-treated HL-60 cells(cell proliferation) using 
haemocytometer 
5FTHF 0 1 2 3 6 
0 µg/ml 1 0.985 1.195 1.185 1.06 
5  µg/ml 1 1.21 1.435 1.575 1.12 
10 µg/ml 1 1.385 1.69 1.84 1.465 
25 µg/ml 1 1.385 2.03 1.975 1.765 
50µg/ml 1 1.565 2.07 2 1.955 
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Figure 3.32 shows 5FTHF doses on UVB-treated HL-60 cells(cell proliferation) using 
haemocytometer 
 
 
 
 
Table 3.33 shows 5FTHF doses on UVB-treated HL-60 cells(cell proliferation) 
5FTHF 0 1 2 3 6 
0 µg/ml 1 0.985 1.195 1.185 1.06 
5 µg/ml 1 1.21 1.435 1.575 1.12 
10 µg/ml 1 1.365 1.69 1.84 1.465 
25 µg/ml 1 1.385 2.03 1.975 1.765 
50 µg/ml 1 1.565 2.07 2 1.955 
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Figure 3.33 shows 5FTHF doses on UVB-treated HL-60 cells(cell proliferation) 
 
 
 
 
 
 
 
3.5.6.2 Flow cytometric  analysis: 
3.5.6.2.1 Control proliferating cell 
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3.5.6.2.2 1 minute UVB exposure - 0µl  5FTHF- day 1 
                                                                                                                                          
 
3.5.6.2.3 1 minute UVB exposure - 0µl  5FTHF- day 2 
                   
                 
3.5.6.2.1 1 minute UVB exposure - 0µl  5FTHF- day 3 
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3.5.6.2.2  1 minute UVB exposure - 0µl  5FTHF- day 6 
                   
                  
3.5.6.2.3  1 minute UVB exposure – 0 µl  5FTHF- overlay: 
                 
    
 
 
 
 
3.5.6.2.4  1 minute UVB exposure - 5µl  5FTHF- day 1 
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3.5.6.2.5  1 minute UVB exposure - 5µl  5FTHF- day 2 
           
          
3.5.6.2.6  1 minute UVB exposure - 5µl  5FTHF- day 3 
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3.5.6.2.7  1 minute UVB exposure - 5µl  5FTHF- day 6 
 
 
3.5.6.2.8  1 minute UVB exposure - 5µl  5FTHF- overlay: 
 
3.5.6.2.9  1 minute UVB exposure – 10 µl  5FTHF- day 1 
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3.5.6.2.10  1 minute UVB exposure – 10 µl  5FTHF- day 2 
           
          
3.5.6.2.11  1 minute UVB exposure – 10 µl  5FTHF- day 3 
              
               
3.5.6.2.12  1  minute UVB exposure – 10 µl  5FTHF- day 6 
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3.5.6.2.13  1 minute UVB exposure – 25 µl  5FTHF- day 1 
 
 
3.5.6.2.14  1 minute UVB exposure – 25 µl  5FTHF- day 2 
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3.5.6.2.15  1 minute UVB exposure – 25 µl  5FTHF- day3 
 
 
 
 
 
3.5.6.2.16  1 minute UVB exposure – 25 µl  5FTHF- day6 
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3.5.6.2.17  Overlay: 
 
3.5.6.2.18  1 minute UVB exposure – 50 µl  5FTHF- day1 
 
 
3.5.6.2.19  1 minute UVB exposure – 50 µl  5FTHF- day2 
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3.5.6.2.20 1 minute UVB exposure – 50 µl  5FTHF- day3 
 
 
 
 
3.5.6.2.21  1 minute UVB exposure – 50 µl  5FTHF- day6 
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3.5.6.2.22 overlay  1 minute UVB exposure – 50 µl  5FTHF 
 
3.5.7 Serum free medium(SFM) - 5FTHF doses – 1-12 days kinetics: 
                 For modulation of 5 folinic acid 70x10
6
 cells were washed extensively in 1x PBS, 
resuspended in Iscove serum free medium,  aliquoted into 5 dishes(14x10
6
 in each  100mm), 
and incubated overnight. Next day cell count and viability were checked. then cells were 
supplemented with or no assigned increasing doses of folinic acid  namely(5,10, 25 and 50 
µg/ml. cells harvested after  1, 2, 3, 6, 9 and 12 days where cell count using haemocytometer, 
cell viability using trypan blue dye exclusion and staining with PI for FACS analysis were 
performed.  
3.5.7.1 Results: 
               The results show that  , HL-60 cells double in number at 3 days, and later decrease in 
number, until completely die at 12 days. Furthermore, administration of 5FTHF increased cell 
growth in SFM, up to 9 days (50ug/ml), while cell death starts at day 6. Proliferation 
compensates death up to day 9. Later death prevails, so the cell number decreases. There is a 
dose dependence of 5FTHF in both proliferation and survival. The findings show that 
administration of 5FTHF is specific and target only to the temporary growth in SFM(p>0.05).  
The results confirmed by flow cytometric analysis, with high- doses of folinic acid there is a 
reduction in sub G1, increase the number of S phase by day 3 and G2 phase indicating, 
however, as time went by there are increase in sub G1, decrease in S and G2 phases indicating 
depletion of  folinic acid, whereas, with low- doses of folinic acid there are elevation in sub 
G1 compared with high- doses folinic acid(p<0.05).   
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Table 3.34 5FTHF doses -1 -12 doses kinetics (cell proliferation) 
5FTHF 0 1 2 3 6 9 12 
0µg/ml 1.015 1.34 1.34 1.865 1.845 1.12 0.05 
5 µg/ml 1.015 1.325 1.55 1.87 2.11 1.555 0.625 
10 µg/ml 1.015 1.51 1.665 1.88 2.33 1.61 0.7 
25 µg/ml 1.015 1.555 1.735 2.09 2.48 2.16 1.31 
50 µg/ml 1.015 1.665 1.76 2.59 2.955 3.38 1.69 
 
                   
 
Figure 3.34 5FTHF doses -1 -12 doses kinetics (cell proliferation) 
 Table 3.35  5FTHF doses -1 -12 doses kinetics (cell survival) 
 
5FTHF 0 1 2 3 6 9 12 
0µg/ml 0.92 0.905 0.87 0.88 0.59 0.29 0.0064 
5 µg/ml 0.92 0.93 0.93 0.92 0.73 0.41 0.13 
10 µg/ml 0.92 0.92 0.93 0.93 0.75 0.44 0.17 
25 µg/ml 0.92 0.93 0.95 0.94 0.79 0.52 0.3 
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50 µg/ml 0.92 0.95 0.954 0.94 0.81 0.64 0.37 
 
 
 
      
Figure 3.35 5FTHF doses -1 -12 doses kinetics (cell survival) 
 
 
 
 
3.5.7.2  Flow cytometry analysis:                
3.5.7.2.1   Starved cells ( control) 
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3.5.7.2.2   SFM- 0 µg/ ml – day 1 
 
 
 
 
3.5.7.2.2   SFM- 0 µg/ ml – day 2 
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3.5.7.2.3   SFM- 0 µg/ ml – day 3 
         
       
3.5.7.2.4   SFM- 0 µg/ ml – day 6 
           
              
3.5.7.2.5   SFM- 0 µg/ ml – day 9 
                     
 110 
 
                   
 
 
 
3.5.7.2.6   Starved control vs. SFM- 0 µg/ ml – day 9 
 
3.5.7.2.7   SFM- 0 µg/ ml – day 12 
 
 
3.5.7.2.8   SFM- 5 µg/ ml – day 1 
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3.5.7.2.9   SFM- 5 µg/ ml – day 2 
         
     
 
3.5.7.2.10   SFM- 5 µg/ ml – day 3 
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3.5.7.2.11   SFM- 5 µg/ ml – day 6 
              
            
 
 
3.5.7.2.12   SFM- 5 µg/ ml – day 9 
            
            
3.5.7.2.13   Starved ( control): 
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3.5.7.2.14   Starved control 001 & 015 vs. SFM- 5 µg/ ml – day 9 014 and 016 
             
 
 
 
 
3.5.7.2.16   SFM- 5 µg/ ml – day 12 
                
                
3.5.7.2.17   SFM- 10 µg/ ml – day 1 
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3.5.7.2.18   SFM- 10 µg/ ml – day 2 
               
                 
3.5.7.2.19   SFM- 10 µg/ ml – day 3 
                     
                   
3.5.7.2.20   SFM- 10 µg/ ml – day 6 
                     
 115 
 
                      
3.5.7.2.21   SFM- 10 µg/ ml – day 9 
               
                
 
 
3.5.7.2.22   Starved ( Control) 
                   
                   
 
3.5.7.2.23   Starved control 001 & 023 vs. SFM- 10 µg/ ml – day 9 022 and 024 
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3.5.7.2.24   SFM- 10 µg/ ml – day 12 
       
        
3.5.7.2.25   Starved ( control) 
           
             
3.5.7.2.26   Starved control overlay: 
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3.5.7.2.27   SFM- 0 µg/ ml – overlay 
 
3.5.7.2.28   SFM- 5 µg/ ml – overlay 
 
3.5.7.2.29   SFM- 10 µg/ ml – overlay 
 
3.5.7.2.30   serum free medium SFM- 25 µg/ ml – day 1 
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3.5.7.2.31   serum free medium SFM- 25 µg/ ml – day 2 
             
               
 
 
 
 
3.5.7.2.32   serum free medium SFM- 25 µg/ ml – day 3 
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3.5.7.2.33   serum free medium SFM- 25 µg/ ml – day 6 
                         
                          
3.5.7.2.34   serum free medium SFM- 25 µg/ ml – day 9 
                  
                 
 
 
3.5.7.2.35   serum free medium SFM- 25 µg/ ml – day 12 
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3.5.7.2.36 serum free medium SFM- 25 µg/ ml   Overlay 
               
3.5.7.2.37 serum free medium SFM- 50 µg/ ml – day 1 
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3.5.7.2.38  serum free medium SFM- 50 µg/ ml – day 2 
                         
                      
3.5.7.2.39  serum free medium SFM- 50 µg/ ml – day 3 
                            
                            
3.5.7.2.40 serum free medium SFM- 50 µg/ ml – day 6 
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3.5.7.2.41  serum free medium SFM- 50 µg/ ml – day 9 
               
                    
3.5.7.2.42  serum free medium SFM- 50 µg/ ml – day 12 
           
              
3.5.7.2.43 serum free medium SFM- 50 µg/ ml overlay 
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3.5.7.2.44 Elaboration of FACS result 
3.5.7.2.45 Serum medium and 5FTHF doses- 1 -12 days free  
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3.5.8 SFM 5FTHF 10x5 vs 50 9-15  days 
              To check if the decreased proliferation observed after day 9 is due to actual 
degradation and depletion of 5FTHF, or rather to exhaustion of proliferative potential. This 
was assessed by testing if a single dose of 50µg/ml  of 5FTHF at day 0 provides similar result 
to multiple administration of 10 µg/ml 5THF from day 0 and given every 2 days. In this 
context  42x10
6
 cells were washed thoroughly in 1x PBS, resuspended in serum free medium, 
after that plated into three dishes(100x15 diameter)  and incubated overnight. Next day doses 
of folinic acid were added namely 0, 50 and 10x5 µg/ml to each plate. Cell number and 
viability were checked. Cells were harvested after 9, 12 and 15 days where cell count and 
viability were performed.  
3.5.8.1 Result: 
            Cells have ceased its proliferation after day 9 much likely due to depletion of folinic 
acid as well as   exhaustion of its proliferative potentiality, as no significant difference 
between administering single dose of 50 µg/ml and multiple doses of 10x5 µg/ml(p<0.05). 
Nonetheless,  cells supplemented with single dose of 50 µg/ml have successfully  doubled 
their number by day 9 then gradually underwent apoptosis compared to the cell that 
supplemented with multiple doses (5x10 µg/ml) which have epic failed to complete one 
complete one  cycle by day 9 then gradually underwent apoptosis en masse. 
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Table 3.36 shows  SFM 5FTHF 10x5 vs 50 9-15 days(cell proliferation) 
    
         
 
Figure 3.36  shows  SFM 5FTHF 10x5 vs 50 9-15-days(cell proliferation) 
 
 
 
 
 
 
 
 
 
 
5FTHF 0 9 12 15 
0 µg/ml 0.995 1.095 0.815 0.12 
5x10µg/ml 0.995 1.665 1.375 0.455 
50µg/ml 0.995 2.1 1.255 0.455 
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Table 3.37 shows s   SFM 5FTHF 10x5 vs 50 9-15-days (cell survival) 
5FTHF 0 9 12 15 
0 µg/ml 0.85 0.33 0.2 0.02 
5x10µg/ml 0.85 0.58 0.38 0.1 
50µg/ml 0.85 0.7 0.39 0.1 
 
 
  
 
         
 
Figure 3.37 shows Table shows s   SFM 5FTHF 10x5 vs 50 9-15-days (cell survival) 
 
 
 128 
 
3.5.9 PBMC SFM 5FTHF doses 1-12 days 
3.5.9.1 Peripheral Blood mononuclear cells PBMCs preparation 
3.5.9.1.1 PBMCs isolation: 
            PBMCs were isolated from buffy-coat bag obtained from S.I.T. FERRARA 
2013015692 (Ferrara hospital Blood bank) by using  standard density gradient centrifugation 
Ficoll 1077. The blood was subsequently diluted by adding  260 ml of  sterile 1x PBS to the 
buffy-coat(40 ml). 36 ml of the buffy coat/saline mixture was carefully layered over 12 ml of 
Lympholyte 
R
- H (CEDARLANE CANADA) in a universal falcon 50 ml  tube ( 8 tubes were 
used) ensuring that a distinct interface between the two layers was maintained. The blood was 
then centrifuged at 1500 rpm for 30 minutes at 4°C  with no brake applied, to ensure 
separation of the PBMCs from the denser Ficoll/erythrocyte layer below, and the less dense 
dilute plasma layer above.  The top plasma level was siphoned off and discarded, while  the 
peripheral blood mononuclear cell layer was then gently removed with a sterile micro pipette 
and placed in a sterile  falcon tube.  The PBMCs were further washed twice with 50 ml of 1x 
PBS and centrifuged at 1500 rpm for 10 minutes with brake applied. Supernatant was 
siphoned off, and the pellet  was washed twice with 1x PBS. The cell pellet was finally 
resuspended in 2-3mls of 1x PBS. The freshly isolated PBMCs were counted by adding 1 ml 
of cell suspension to 9 ml of 1x PBS. 10μl of this mixture was thoroughly mixed, and loaded 
in a haemocytometer (Neubauer). Cells were counted and resuspended in Iscove serum free 
medium overnight(modified from Lan et al., 2007) 
3.5.9.1.2 Cells culture and 5FTHF doses: 
              Cells were grown in serum- starved Iscove medium. Next day  cells were plated into 
4 duplicates 50x10
6
/15 ml per each. First duplicate supplemented with or no 1% foetal bovine 
serum(400 µl/15 ml). Second duplicate in addition to presence or absence of serum they 
further treated with phytohaemagglutinin PHA375 µl/15 ml ). Third duplicate in addition to 
presence or absence of serum they were treated with PHA and 50 µg/ml of folinic acid. The 
last duplicate supplemented with or no serum in addition 50 µg/ml of  folinic acid. Cells were 
incubated overnight at humidified atmosphere.. cells were harvest cell at day 1, 2, 3, 6, 9 and 
12 thereby cell count and viability were performed.  
3.5.9.1.2.1 Results: 
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               According to its baseline cells grown in 1% serum increase their number by day 2 
then steadily levelled off their number compared to cells that grown in serum deprived 
condition, however no significant difference(p˂ 0.05). stimulating cells with PHA in presence 
of serum is crucial as it leads cells to  proliferate as shown herein cells increase a bit their 
number by day 6( p> 0.05). Whereas cells grown in absence of serum their growth was 
abrogated and thus  underwent apoptosis. Folinic acid supplemental doesn’t induce profuse 
proliferation since cells supplemented with serum and folinic acid doubled its number by day 
2 then began to level off its number, whereas cells maintained in serum free medium its 
number increased a bit and afterward underwent apoptosis en masse(p˂ 0.05). Cells 
supplemented with serum and folinic acid and later activated with PHA increased its number 
by day 6. Nonetheless,  its number is far from the baseline. while its counterpart which grown 
in absence of serum underwent apoptosis en masse( p> 0.05).   
Table 3.38  shows cells proliferation in absence of serum  
  1 2 3 6 9 12 
0 % FBS 0.785 1.532 0.73 0.665 0.4 0.28 
PHA/ 0%FBS 0.18 0.045 0.04 0.035 0.04 0.005 
0% FBS+ 5FTHF 1.08 1.325 1.11 0.64 0.615 0.28 
PHA/0% FBS+5FTHF 0.06 0.075 0.05 0.03 0.045 0.04 
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Figure 3.38 shows  cells proliferation in absence of serum   
 
Table 3.39 cell survival in absence of serum 
  1 2 3 6 9 12 
0 % FBS 0.31 0.36 0.23 0.16 0.06 0.06 
PHA/ 0%FBS 0.31 0.05 0.03 0.013 0.011 0.007 
0% FBS+ 5FTHF 0.23 0.31 0.28 0.08 0.08 0.03 
PHA/0% FBS+5FTHF 0.08 0.06 0.04 0.014 0.015 0.01 
 
 
Figure 3.39  shows  cell survival in absence of serum 
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Table 3.40 shows cell proliferation in presence of ( 1% serum) 
  1 2 3 6 9 12 
1 % FBS 1.55 2 1.91 1.27 0.8 0.53 
PHA/ 1%FBS 0.32 0.335 0.31 0.525 0.48 0.305 
1% FBS+ 5FTHF 1.825 2.505 2.1 1.585 0.957 0.54 
PHA/1% FBS+5FTHF 0.46 0.32 0.565 0.59 0.845 0.285 
 
                 
Figure 3.40 shows  Cell proliferation in presence of  1% serum    
Table 3.41 shows  cell survival in presence of 1% serum) 
  1 2 3 6 9 12 
1 % FBS 0.34 0.43 0.43 0.31 0.15 0.11 
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Figure 3.41 shows  cell survival in presence of 1% serum 
3.5.10  SFM 5FTHF maximal effective dose 
               To determine which is the minimal doses that produces maximal proliferating 
response at 9-15 days of culture. After being  washed extensively in 1x PBS, HL- 60 cells 
cultured in serum free medium grew comparably with cells supplemented with different 
concentration of folinic acid 0, 50, 10, 200 and 400 µg/ ml respectively. Cells were harvested 
after 6, 9, 12 and 15 days thereby cell count and viability were performed, 
3.5.10.1 Results:  
            Folinic acid effectively induces cellular proliferation in absence of growth 
factor(p>0.05). In this context cells seeded in 5FTHF restriction  Iscove serum free medium 
proliferate but  nearly  complete one cycle , where-upon their numbers sharply,  began 
PHA/ 1%FBS 0.36 0.25 0.2 0.16 0.113 0.04 
1% FBS+ 5FTHF 0.34 0.51 0.42 0.24 0.13 0.06 
PHA/1% FBS+5FTHF 0.35 0.21 0.24 0.15 0.12 0.05 
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declining by day 9.  whereas cells  maintained in Iscove serum free media and supplemented 
with varying concentration of 5FTHF they more or less double their number twice indicating 
they have entered two cycles. Then  their number  steadily reduced by day 12 in dose 
dependently manner implying degradation and consuming of folate. . Moreover 50 µg/ml 
could be the minimal dose that could induce maximum proliferation Surprisingly, No much 
difference between administering 100 and 200 µg/ml(p˂0.05).  
 
Table 3.42 shows - SFM- 5FTHF maximal effective dose ( cell proliferation) 
 
5FTHF 0 6 9 12 15 
0 µg/ml 1.075 1.93 1.805 1.445 0.83 
50 µg/ml 1.075 2.535 2.965 2.13 1.565 
100 µg/ml 1.075 2.67 3.35 2.62 2.37 
200 µg/ml 1.075 2.66 3.34 2.605 2.375 
400µg/ml 1.075 3.03 3.69 2.875 2.55 
 
        
Figure 3.42 shows Table shows - SFM- 5FTHF maximal effective dose ( cell proliferation) 
Table 3.43 shows  SFM- 5FTHF - maximal effective dose (% cell survival) using trypan 
blue exclusion 
 
5FTHF 0 6 9 12 15 
0 µg/ml 0.92 0.7 0.39 0.23 0.1 
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50 µg/ml 0.92 0.78 0.6 0.41 0.22 
100 µg/ml 0.92 0.8 0.64 0.47 0.29 
200 µg/ml 0.92 0.82 0.66 0.52 0.3 
400µg/ml 0.92 0.82 0.68 0.52 0.33 
 
 
 
Figure 3.43 shows  SFM- 5FTHF - maximal effective dose (% cell survival) using trypan blue 
exclusion 
3.5.11 Effect of 5FTHF supplemental on cell proliferation using HL-60: 
                To determine therefore, whether 5FTHF supplemental might involve in inducing 
changes in proliferation among HL- 60. Thereby cells were maintained in Iscove medium 
supplemented with 5% foetal bovine serum, then plated into two dishes namely 5FTHF 
supplemental ( supplemented with 50 µg/ ml), and 5FTHF deprived, then incubated overnight 
at 37°C in an atmosphere of 95% air and 5% CO2 . Cells were harvested after 1,2 and 3 days 
where cell count and viability were performed.  
3.5.11.1  Results: 
              cells which grown in absence of  5FTHF exponentially  quadrupled their number by  
48h then its nearly proliferate to complete one cycle. Whereas 5FTHF supplemental cells   
slowly quadrupled their number by 72 but they didn’t reach the number of its counterpart(p<. 
Considering  cell survival cells grown in absence of 5FTHF  steadily increase in cell survival 
then began to decline a bit by 72h, whereas cells seeded in presence of 5FTHF slow decline by 
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24h then began to increase by 72h might it needs time to acclimatize to toxicity induced by 
folinic acid. 
 
 
 
 
 
 
Figure 3.44 shows table shows effect of 5FTHF supplemental on HL-60 (cell proliferation) 
Table 3.44 shows effect of 5FTHF supplemental on HL- 60 ( Cell proliferation using 
haemocytometer  
 
  0 1 2 3 
5FTHF(-ve) 1 2.56 4.165 4.94 
5FTHF(+ve) 1 1.695 2.78 4.395 
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Figure 3.45 shows table shows effect of 5FTHF supplemental on HL-60 (cell proliferation) 
Table 3.45  illustrate Effect  of 5FTHF supplemental on HL-60 (cell survival) using trypan blue 
exclusion  
  0 1 2 3 
5FTHF(-ve) 0.85 0.88 0.89 0.87 
5FTHF(+ve) 0.85 0.8 0.84 0.86 
 
 
Figure 3.46 illustrate Effect  of 5FTHF supplemental on HL-60 (cell survival) using trypan blue 
exclusion: 
 137 
 
 
Figure 3.47 illustrate Effect  of 5FTHF supplemental on HL-60  (cell survival) using trypan blue 
exclusion 
3.5.12 Effect of 5FTHF supplemental on cell proliferation using MCF-7 cell: 
               To determine therefore, whether 5FTHF supplemental might involve in inducing 
changes in proliferation among MCF-7 cell lines.              3x10
6
 were maintained in Iscove 
medium, supplemented with 5% foetal bovine serum. Then aliquoted into 6 dishes(35x10 
mm), three dishes among them further supplemented with 50 µg/ml hence described as folinic 
acid supplemental while the other 3dishes described as folinic acid restriction cell. Cells were 
incubated in humidified atmosphere and cell harvested at day 1, 2 and three (each dish 
represent a day). 
3.5.12.1 Results: 
             Folinic acid restriction cells exponentially proliferate culminating its proliferative 
capacity by day 3. Whereas the folinic acid supplemental cell decrease its number by day 1 
and nearly reach the baseline by day 2 and nearly doubled their number by day 3 (p<0.05). 
Table 3.46 shows effects of 5FTHF supplemental on cell proliferation using MCF-7: 
status  0 1 2 3 
FA(+) 0.5 0.29 0.455 0.96 
FA(-) 0.5 0.615 0.9 1.874 
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Figure 3.48  describes  Effect of 5FTHF supplemental on cell proliferation using MCF-7 cell 
 
Table 3.47 shows the effects of 5FTHF supplemental on cell proliferation using MCF-7 
(cell survival)   
 status 0 1 2 3 
FA(+) 0.93 0.84 0.84 0.9 
FA(-) 0.93 0.94 0.98 0.95 
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Figure 3.49 shows effects of 5FTHF supplemental on cell proliferation using MCF-7 (cell 
survival) 
3.5.13 c-Myc inhibition and rescue with 5FTHF: 
                 20x10
6
 cells were grown in Iscove Modified Dulbecco's Medium, supplemented 
with 5% foetal bovine serum, then cells were plated into 4 dishes, the first two dishes treated 
with c-myc inhibitor 10058-F4(sigma) and supplemented with or no folinic acid. Whereas the 
other two dishes supplemented with DMSO(Fischer life sciences) with  or no folinic acid. 
Cells were harvested at day 1,2 and 3 whereby cell count and viability were performed, and 
cells were fixed and permeabilized for flow cytometric analysis. 
3.5.13.1  Result: 
                Cells treated with c-Myc inhibitor 10058-F4  with no folinic acid supplementation 
there is tremendous drop in its number and viability as well and the drop reached its nadir by 
day 3(p>0.05). Whereas folinic acid partially bypass the effect of c-Myc inhibitor in cells 
treated with c-Myc  inhibitor 10058-F4(p˂0.05),  however , the cell number is far from the 
baseline. There is a proliferative inhibition in The folinic acid supplemental cell  compare to 
folinic acid restriction cells(p˂0.05), at day for cells that treated with 10058-F4,  the flow 
cytometric analysis shows peak sub G1 indicating apoptosis, supplementation of folinic acid 
has no real effect at day 3 as indicated by accumulation of cells at sub G1. Folinic acid 
supplementation slightly inhibits cell proliferation compare to folinic acid deficient cells.   
               
Table 3.48 shows the effect c-Myc inhibition and rescue with 5FTHF( cell proliferation) using 
haemocytometer: 
 0 1 2 3 
FBS/10058/FA 1 1.365 0.815 0.3` 
FBS 1 0.89 0.455 0.125 
FBS/FA/DMSO 1 1.56 2.22 2.805 
FBS/DMSO 1 1.88 2.395 3.615 
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Figure 3.50 shows c-Myc inhibition and rescue with 5FTHF( cell proliferation) using 
haemocytometer 
Table 3.49 shows c-myc inhibition and rescue with 5FTHF Cell survival) using trypan blue 
dye exclusion: 
  0 1 2 3 
FBS/10058F4/FA 0.96 0.64 0.34 0.11 
FBS/10058F4 0.96 0.48 0.21 0.04 
FBS/FA/DMSO 0.96 0.89 0.85 0.84 
FBS/DMSO 0.96 0.92 0.89 0.9 
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Figure 3.51 shows Table shows c-myc inhibition and rescue with 5FTHF Cell survival) using 
trypan blue dye exclusion: 
 
 
 
3.3.13.2  Flow cytometric analysis: 
3.5.13.2.1  stained proliferating control: 
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3.5.13.2.2  proliferating cells treated with anti c-myc 10058-F4- day 3: 
 
 
 
 
3.5.13.2.3  proliferating cells treated with anti c-myc 10058-F4 and  folinic acid- day 
3: 
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3.5.13.2.4  proliferating cells treated with folinic acid and DMSO- day 3: 
 
 
 
 
 
 
 
 
3.5.13.2.5   proliferating cells treated with DMSO- day 3: 
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3.5.13.3 Mitotic index: 
             100 µl of Colcemid(Gibco) was added to a flask containing 10 ml of cell culture for 90 
minutes. Then solution was transferred into 15 ml falcon tube. Then centrifuged at 2040 rpm 
for 10 minutes. Then supernatant was siphon off leaving only 2 ml. The pellet was vortexed 
and hypotonic solution(0.47 g potassium chloride K Cl was dissolved in 100 ml distilled water 
DW and kept in water path at 37°C), was added dropwise until 4ml then the volume completed 
to 14 ml. Then the falcon tube was put in water path at 37°C for 22 minutes. After that 
centrifuged at 2000 rpm for 10 minutes, and at the same time fixative solution (3 volumes of 
ethyl alcohol were added to 1 volume of acetic acid) was prepared. The supernatant was 
siphon off leaving only 2 ml. The was resuspended, and fixative solution was added dropwise 
while vortexing first to 3 ml then the volume completed to 14 ml, and left for 45 minutes at 
room temperature RT. Then centrifuged at 2040 rpm for 10 minutes. The supernatant was 
siphon off leaving only 1.5 ml. Then the pellet was resuspended and 3:1 fixative solution was 
added dropwise while vortexing and volume completed to 10 ml. Then centrifuged at 2040 
rpm for 10 minutes. The supernatant was siphon off leaving only 1 ml. Then the pellet was 
resuspended and   fixative solution was added dropwise and the volume completed to 10 ml. 
Then centrifuged at 2040 rpm for 10 minutes.  The slide was prepared by dropping the swollen 
fixed cells onto microscopic slide and left to dry. Then the slide was stained using Giemsa 
stain(20 ml of Giemsa diluted in 80 ml of disodium hydrogen phosphate Na2 HPO4, pH 
6.8).the mitotic indices were calculated using the following equation  
Mitotic index MI =             
  Wherefore the number of examined metaphase cells represented the mitotic division since the 
Colcemid substance blocked the mitotic division at metaphase. 
3.5.13.3.1   Mitotic index of cells treated with c-myc inhibitor and rescue with folinic 
acid: 
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                 To determine the mitotic index, 15x10
6
 cell were seeded in Iscove medium, 
supplemented with 5% Fetal bovine serum. Cells were equally plated into three dishes 5x10
6
 
per each. Then treated with Colcemid(50 µl/5ml) for three hours. the first dish was treated  
with c-myc inhibitor(10058-F4). The second treated with c-myc inhibitor in addition to folinic 
acid. The last one  was left untreated(control). Then incubated overnight. Next day cell treated 
as mentioned above. 
3.5.13.3.1.1 Result: 
              Cells that has been treated with c-myc inhibitor has shown low mitotic activity 
compared to same cells which has been supplemented with folinic acid. Confirming that 
folinic acid may bypass the effect of anti c-Myc as shown in the figure below.    
 
Figure 3.52 describes the mitotic activity   
 
3.5.13.4   synchronization of cells with methotrexate and treatment with c-myc inhibitor: 
                   30x10
6
 cells were maintained in Iscove medium, supplemented with 5% fetal 
bovine serum. Then plated into six dishes(5x10
6
 per each),. 3 dishes  represent one group that 
released from the block after 3 hours. and rest represent another group that released from the 
block after 5 hours. Each dish was treated with 257 µl of methotrexate(lederle) for 16 hours. 
Next day cell were washed with  sterile1x PBS, resuspended  in Iscove medium supplemented 
with 5% FBS. 3h and 5 h latter cells were released from the block by adding 50 µl of 
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Colcemid(Colchicine). Then treated with c-myc inhibitor, c-myc inhibitor and folinic acid and 
untreated cells,  and incubated overnight, next day cells were treated as  mentioned above. 
3.5.13.4.1   Results: 
               With regard to cells that  have being released from the block after 3 hours,  the 
obtained results show that, the mitotic activity has shown reduction in  c-Myc inhibitor treated 
cell, while administration of folinic acid has increased the mitotic activity in c-Myc inhibitor 
treated cell, generally speaking there are a reduction in both cells compare to control.  
Concerning cells that have being released from the block after 5 hours. Intriguingly there is a 
reduction in the mitotic activity. 
          
Figure 3.53 shows mitotic activity of cells that has been released from the block after 3 hours 
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Figure 3.54 shows mitotic activity of cells that has been released from the block after 5 hours   
3.5.13.5   Flow cytometric analysis for synchronization of cells with methotrexate and treatment with 
c-Myc inhibitor    
                   Cells were seeded at density of 40x106 cells and  maintained in Iscove medium, 
supplemented with 5% foetal bovine serum. Then plated into six dishes(5x106 per each),. 3 
dishes  represent one group that released from the methotrexate block after 3 hours. And the 
rest represent another group that released from the methotrexate block after 5 hours. In 
addition to control group that treated with methotrexate. Each dish was treated with( 0.1 mM) 
257 µl of methotrexate(lederle) for 16 hours. Next day cell were washed with  sterile 1x PBS, 
resuspended in Iscove medium supplemented with 5% FBS. 3h and 5 h later cells were 
released from the block by. Treating it with c-myc inhibitor, c-myc inhibitor and folinic acid 
and untreated cells, afterward  adding 50 µl of Colcemid. The cells were prepared for flow 
cytometric analysis using the protocol.       
3.5.13.5.1 Results:  
             We intended to synchronize cells in S phase, then determine the effect of anti-c-Myc, 
moreover, to determine the capacity of folinic acid to rescue cells. By serendipity We added 
high amount of methotrexate 0.mM which results in trapping and freezing cells at G0/G1, 
however this treatment abrogate the action of anti c-Myc. Meanwhile administration of folinic 
acid helps cell a bit to traverse the S- phase and continued the cell cycle 
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3.5.13.5.1.1  MTX synchronized cell(control): 
 
 
 
 
3.5.13.5.1.2  MTX synchronized cells that have being  treated with anti c-Myc(10058-F4)- 3h after 
the block: 
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3.5.13.5.1.3 MTX synchronized cells that have being treated with anti c-Myc(10058-F4) and FA- 3h 
after the block: 
 
 
 
 
3.5.13.5.1.3  MTX synchronized cells- 3h after the block: 
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3.5.13.5.1.4 MTX synchronized cells that have being treated with anti c-myc(10058-F4)- 5h after the 
block: 
 
 
 
 
3.5.13.5.1.5 MTX synchronized cells that have being treated with anti c-myc(10058-F4) and FA- 5h 
after the block: 
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3.5.13.5.1.6 MTX synchronized cell- 5h after the block: 
 
 
 
 
  3.5.13.5.1.7 proliferating cells control: 
 
 
 
 
 
 
 
 
 
 152 
 
 
 
 
4- Discussion 
              It is well-known that, short wavelength UV radiation (UVC) elicits predominantly 
DNA damage to cells by forming pyrimidine dimers and 6-4 photoproducts. These DNA 
lesions can cause cytotoxicity by activating death pathways or  inhibiting transcription and 
replication which consequently result in apoptosis(Ljungman et al., 1999; Gentile et al., 2003). 
The results obtained in the present study show that UVC can induce prominent apoptosis in 
HL-60 as easily identified by trypan blue dye exclusion. However, the manner and modality of 
action and the sequel of the event seem to be dose – dependent. As reported by Latonen et al., 
(2001), that in response to low dose of UV radiation, DNA replication is repressed and the 
cells undergo a transient arrest re-entering the cell cycle by 24 hours. Instead, a high dose of 
UV damage results in initial replicative arrest followed by death of the cells via apoptosis. Our 
findings consistently agree with this, since after supplementing cells with fetal bovine serum 2 
hours post radiation, cells that were exposed to low dose of UVC awesomely restored and 
reverted their proliferative capacity nearly to untreated one(p<0.05). Nevertheless cells that 
were exposed to high dose of UVC underwent apoptosis en masse. Additionally, UV 
irradiation may induce apoptosis by activating cell surface death  receptor CD-95. Lu et al., 
(1996), reported activation of p36 myelin basic protein(MBP) kinase specifically associated 
with cells undergoing apoptosis.       Furthermore this finding could be imputed to the 
supplementation of fetal bovine serum which contains growth factors(GFs), which are not only 
implicated in survival signaling, cell migration, metastasis formation and angiogenesis, but 
also confer a reduction in the response of tumour cells to cytotoxic compounds. Also growing 
amount of evidence has indicated that the intracellular redox state plays a paramount role in 
the mechanism action of GFs. Particularly,  GFs have been reported to produce reactive 
oxygen species (ROS), which may function such as proliferation and programmed cell death( 
Thannickal and Fanburg, 2000; Melisi et al., 2004).  
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                 5-formyltetrahydrofolate is an ubiquitous member of  folate biological pool, usually 
constituting about 10- 25% of total cellular folates(Cossins, 1984; Horne et al., 1989). It is 
long- established as a nutrient supplement, and is capable of inhibiting cytotoxicity and 
chromosomal damage elicited by chemicals. The results presented in our study show that 
folinic acid induce cell proliferation in UVC untreated cells, however, in UVC treated cells 10 
and 25 µg/ml of folinic acid had no real effects on UVC treated cells probably the amount of 
folinic acid not instrumental enough to rescue inflicted cells, while cells supplemented with 
hyper-physiologic dose(400 µg/ml) can sparsely out compete the cytotoxicity induced by UVC 
and sustains cell viability without restoring the proliferative capacity. This finding is in an 
accord with study conducted by Keshava et al., (1996), who pointed out that folinic acid had 
minimal effect in reversing the cytotoxicity induced by UVC and X-rays radiations.  The most 
likely explanation for the inhibition of  radiation induced chromosome aberrations could be a 
reduction in the number of single strand breaks(SSBs)prior to their conversion into double 
strand breaks(DSBs). Furthermore, several lines of evidence indicate that folate depletion 
alone accounting for DNA strand breaks equal to 26 cGy of radiation, as following  400 cGy 
of irradiation folate depleted cells exhibited strand breaks to a dose of 710 cGy. These 
observations suggest that, folate deficiency acts synergistically with carcinogen to magnify the 
genetic damage((Branda and Blickensderfer, 1993). Nonetheless, in the present study no folate 
deficiency,   UVC inflicted severe damage that minimally reversed by supplementing folinic 
acid which might impact the synthesis and repair of DNA after damage. Following DNA 
damage slight amount of DNA repair occurs inside the cell utilizing the nucleotide pool exist 
in the cell. Since UVC radiation causes excessive breaks which could result in shortage and 
run out of  nucleotide pool resulting in a defect of repair mechanism. In contrary 
supplementation of folinic acid could assist in generation of the de novo nucleotide pool. 
Thanks to Dihydrofolate reductase well recognize to mediate the reduction  of dihydrofolate 
into tetrahydrofolate, a known cofactor  needed for synthesizing thymidylate, important for 
DNA synthesis. Needless to say that,. Folinic acid is important in DNA synthesis and repair 
and may play an important role in preventing DNA mutations that lead to cancer. 
Additionally, deficiencies in micronutrients including folate have been indicated as a major 
cause of DNA damage, as shown in normal lymphocytes grown in low folate medium exhibit 
excessive DNA strands breaks and increased uracil misincorporation even at folate 
concentrations within the normal range observed in human plasma. In humans, folate 
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depletion causes both massive incorporation of uracil into DNA and chromosome breaks, 
which can be reversed by administering folate (Wei et al., 2003).      Concerning the effects of 
pre and post- treatment and UVC on cell proliferation. We found no marked difference 
between pre and post treatment(p˂0.05), despite there is evolving body of evidence that 
exposure to UV irradiation might result in folate depletion(Williams and Jacobson, 2010). 
                 Ultraviolet B(UVB) radiation is a potent apoptotic trigger in many cell types, in 
tumour and normal cells as well. Many studies have described that UVB- induced cell death 
via the generation of reactive oxygen species, which consequently result in the impairment of 
cellular antioxidants, induction of DNA damage and eventually occurrence of 
apoptosis(Salucci et al., 2012). The data presented in this study demonstrate that, UVB can 
induce irrefutably noticeable damage on HL-60. Nevertheless, the interplay and modus 
operandi are dose- dependent. Low dose of UVB(1 minute), elicits minimal adverse effect, 
while high-dose(10 minutes) cause apoptosis in medias res. Our findings are reasonable 
concordance with Al-Mohanna et al., (2001). The minimal adverse effects induced by low 
dose of UVB is attributed to the behavior of UVB in inducing cyclobutane pyrimidine dimers 
CPDs. These bulky DNA lesions are  removed by nucleotide excision repair. Accordingly,  
temporary arrest at diverse phases of cell cycle is occurred. This process is needed for coherent  
repair of  DNA lesions. The genomic custodian guard p53 plays fundamental role in the 
cellular response to DNA damage. Moreover , p53 protein has a tremendous role in the γ-ray-
induced cell cycle delay in G1 phase.  Surprisingly, HL-60 is p53 deficient cells thus 
indicating that there is an alternative p53- independent pathway causes the delay in G1. Study 
by Al-Mohanna et al., (2001), reported that Hl-60 undergo p53 independent cell cycle arrest. 
Regarding UVB high dose, HL-60 underwentp53- independent apoptosis en masse likewise 
UVC proving that it might be a killing dose. Folinic acid is indispensable for nucleotide 
excision repair, a mechanism used to eliminate the detrimental consequences of DNA damage 
induced by cyclobutane pyrimidine dimers and photoproduct adducts. Folinic acid mitigate the 
adverse effects produced by CPDs notably in low- dose UVB treated cells. While in high- 
dose UVB treated cells which triggers excessive DNA bulky lesions, folinic acid 
supplementation minimally protect cells from apoptosis most probably to the excessive 
amount of  CPDs. Intriguingly folinic acid at concentration 100 µg/ml was found to modulate 
cell growth for untreated cells, additionally,  maintain proliferation, protect cells from 
apoptosis as well as survival of low- dose UVB treated cells(0.5 and 1 minute), indicating dose 
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dependence is premised on dose of  UVB exposure. Interestingly, low- dose UVB(2 minutes 
exposure) seems to be detrimental dose with same effect of 10 minutes, it is hard to identify 
exactly the mechanism behind that, since  in theory no much difference between 1 and 2 
minutes. Unfortunately folinic acid fails to reverse the damage induced relatively low- dose 
UVB suggesting that the excessive underlying damage is beyond the capacity of the repair 
system.  However,  HL-60 is well known as sensitive cells against apoptosis inducing agents 
such as UV irradiation(Sonoda et al., 2000), implying that folinic acid has minimal protection 
effect against relatively low- doses as well as high- doses UVB. Moreover, HL-60 is a 
malignant cells having a reduced rate of folinic acid transport, and therefore, are preferentially 
harmed by high doses of chemotherapy (Golan et al., 2011). Surprisingly the corollary low-
dose UVB synergistically has been enhanced and promoted cell proliferation in cells 
supplemented with high- doses of folinic acid. However, we couldn’t substantiate this process, 
thankfully, It has observed that UV could induce  Unscheduled DNA synthesis (UDS) in 
human lymphocyte(Mohankumar et al., 1998). Huang et al., (1996), reported that UV activates 
growth factor via reactive oxygen intermediate(ROI). Furthermore,    several mechanism can 
be considered to explain the swift EGF receptor activation by UV, one is that UV elevates the 
secretion of EGF- like ligands or other factors that consequently activate the receptor. A 
second likelihood is that UV brings about the production of ROI that trigger the UV signal 
pathway. Alternatively, damaged DNA produces an effect on EGF receptor protein (Huang et 
al., 1996).  
                   The term serum starvation, serum deprivation, depletion, removal, restriction, 
withdrawal as well as serum limitation have been used to denote different procedures that 
include growing cells in either reduced serum, serum free(SFM), or serum and protein- free 
medium(Pirkmajer and Chibalin, 2011). The data presented in this study suggest that the 
administration of 5FTHF has effect on temporary proliferation of HL-60 cells in SFM (that is 
dose-dependently prolonged), whereas has limited effect on cell survival (that is just partially 
reduced in slope) and no effect on UVB resistance. However, our findings are in contrast with 
findings of  Balk et al., (1978), they found that, the normal and Rous sarcoma virus- infected 
fibroblast has proliferated at maximal, again nearly identical rates in in medium containing a 
physiological concentration(10 ng/ml). similar results reported by Chello and Bertino, (1973) 
who found that physiological concentration of 5- methyltetrahydrofolate would support 
maximal proliferation of L-5178Y mouse leukemia cells in culture. Furthermore, no increase 
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in the rate of proliferation was noticed in media containing  supra-physiologic concentration 
(100ng/ml). Nevertheless, in regard to  sub-physiological concentration(0.1ng/ml), a reduced 
proliferative rate was observed which in tantamount with our finding, this difference may 
ascribed to cell type specific behaviour. Folate deficiency has been found to slow down the  
proliferation of varied cell types, not surprisingly cells devoid folates accumulate in the S 
phase possibly due to impaired nucleotide excision repair and slow DNA synthesis, increased 
uracil misincorporation and DNA damage. However when folate is replenished to folate- 
deprived cells, reversal of the S phase accumulation and proliferation is revived. Folate 
deficiency is more likely to affect proliferative cells, which have a higher nucleotides 
requirement (Choi  et al., 1998; Courtemanche et al., 2004).  It is well- observed that cells  cease 
proliferation after day 9 and sub G1 peak was evident, this possibly maybe either due to actual 
depletion of folinic acid. In this context we found no significant difference between 
administering single dose of 50 µg/ml, and replenishing  cells with 10 µg/ml every 2 
days(p<0.05),     or would rather limitation of the proliferative capability,  it is well- 
recognized that a novel mode of apoptosis induction observed in human leukemic HL-60 cells. 
These cells spontaneously underwent apoptosis in the course of proliferation when the cell 
density become higher than 1 x 10
6 
/ ml(Saeki et al., 2000). HL-60 is unique human leukemic 
cell line capable of seemingly infinite proliferation in suspension culture (Collins et al. 1977). 
And the consequential DNA replication and cell division occur at an accelerated rate, folate 
depletion results in  an ineffective DNA synthesis, leading to repression of cell 
growth(Kamen, 1997).  
                   To verify the proliferative response  to folinic acid  in starved HL-60. We check 
the proliferative response to 5-FTHF in normal peripheral blood mononuclear cell(PBMCs), 
under different stringent conditions. The data presented show that, Folinic acid had a 
beneficial effects particularly when combined with serum as it synergistically enhanced cell 
proliferation. However the number of cells haven’t reverted to baseline level(p<0.05). Not 
surprisingly the results show that serum is crucial for cell proliferation. Furthermore, it is well 
evident when cells have been stimulated with mitogen like PHA as in absence of serum 
intriguingly,  PHA seems acting as apoptotic trigger. It has been published that mitogen as 
phytohaemagglutinin may induce lymphocyte to mitogenesis (DNA synthesis) and 
cytotoxicity(lysis of target cell)( Dawkins and Zilko, 1975. Furthermore, activation of PBMCs 
with mitogen leads to proliferation. Nevertheless, under certain conditions, principally when 
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cells are quiescent and restimulated,  it can result in the induction of  apoptosis. This type of 
cell death in PBMCs has been called activation- induced cell death(AICD)( Pahlavani and 
Vargas, 2001). PHA involved activation of caspase-3 and the anti- apoptotic protein Bcl-2 in 
addition to PARP cleavage, suggesting that PHA induces apoptosis via different 
pathways(Nielsen et al., 2007). PHA might work as double- edged sword in presence of 
growth factor enhances cell proliferation while in absence of growth factor accelerates cell 
apoptosis, Hypothesizing that deficient of folate may result in uracil misincorporation and as a 
consequence cells undergo apoptosis. Alternatively maybe imputed to the cell type specific 
and the  amount of serum, we used 1% which considered by others as serum free medium. 
                  Supplementation of  cells with high doses of 5FTHF  dramatically affect cells in 
terms of proliferation and survival as cells proliferate steadily compared to cells grown in 
5FTHF restriction. We observed that folinic acid at concentration 50 µg/ml could be the 
minimal dose to elicit maximal proliferating response by expanding folate pool in malignant 
cells; however this finding seemingly in discordance with the hypothesis hypothesizing  that 
malignant cells have a reduced rate of folinic acid transport (Golan and Tashjian, 2011). In 
contrast  it has been published  recently that excessive folate supplementation may also 
diminish the activity of antifolate drugs that influenced by influenced by a higher intracellular 
folate content(Chattopadhyay et al., 2007). 
                     It is widely accepted that folinic acid preferentially rescues normal cells but does 
not rescue cancer cells; however, this selective rescue is not well elucidated. Leucovorin 
competes with MTX for DHFR binding sites allowing for enzyme reactivation and restoration 
of reduced folate stores preconditioned  for DNA/RNA synthesis(Suh-Lailam et al., 2013). 
Intriguingly, in the present study We noticed that the simultaneous supplementation of folinic 
acid and FBS  inhibit the proliferation of HL-60 cells particularly in the first two days, same 
finding corroborated by testing MCF-7, which exhibit similar phenomenon,  suggesting that it 
is  not a cell type specific phenomenon. Consistently, it has been recently suggested that folic 
acid which works in similar way as folinic acid that  Folic acid  and its metabolite 5-MTHF 
inhibit EGFR promoter activity in colon cancer cells by promoting and enhancing methylation 
of the promoter. This could partly be accounting for folic acid mediated inhibition of growth – 
related processes in colorectal neoplasia(Nagothu et al., 2004). Furthermore, it has been 
evidenced that folic acid governs and control IGF-1R gene expression in colon cancer cells via 
mechanism(s) involving transcriptional suppression of IGF-1R promoter(Attias et al., 2006). 
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The latter finding in harmony with concept that the chemopreventive  functionalized via folic 
acid maybe linked to its capacity to inhibit IGF-1R levels. Below a certain IGF-1R threshold 
level. The capability of most cells to engage in mitogenic activity is significantly impaired( 
Rubini et al., 1997).  
                     Global hypomethylation results in activation of oncogene, transposition of 
repetitive elements, chromosomal instability commonly observed in solid tumours. Among 
these hypomethylated sequences is c-Myc(Mani and Herceg, 2011). C-Myc, a proto-oncogene 
encodes a protein that regulates cellular proliferation and differentiation. Alteration in the 
stability of c-Myc mRNA may lead to overexpression of the gene, and eventually resulting in 
uncontrolled cell growth(Coulis et al., 2000). In the present study we abrogate the activity of 
c-Myc  using anti- c-Myc inhibitor 10058-F4, has been known to preclude the dimerization of 
c-Myc to its client Max, and an a priori and inevitability  suppression of cells proliferation and 
triggering of apoptosis. 10058-F4 has been found to be instrumental in inhibiting cell 
proliferation.it has been published that, c-Myc  not only can increase the cell cycle regulators 
such as cyclin D1, cyclin D2, CDK4, but also can decrease the expression of p21 and 
p27(Roussel et al., 1995).. Importantly, it has been observed that, 10058-F4 arrests the cell 
cycle at (G0/G1 phase)and triggers apoptosis upon expanded treatment most probably by 
increasing cyclin dependent kinase inhibitor, p21WAF! And decreasing cyclin D3 levels, 
additionally, 10058-F4 also remarkably decreases the Alpha- fetoprotein levels, an indicator 
for hepatocellular carcinoma(Lin et al., 2007).  Furthermore, it has been shown that, 10058-F4 
upregulate p21 via p53- independent. In accordance as HL-60 lacks p53(Huang et al., 2006). 
Also Zirath et al., (2013), have demonstrated that 10058-F4 inhibits MYCN signaling in NB 
cells, resulting in cell cycle arrest, apoptosis and/or differentiation as well as reduction of 
tumour growth in aggressive mouse models of NB. Interestingly We observed that  Folinic 
acid administration could partially  bypass and reverse the adverse effects of anti-  c-
Myc(p<0.05). possibly by reviving and  restoring the growth capacity of c-Myc. It is well 
recognized that folinic acid is synthesized from 5,10-methenyltetrahydrofolate by both 
mitochondrial and cytoplasmic isoform SHMT(Stover and Schirch, 1990). Hypothesizing that 
folinic acid can functionalize and mimic same role as mSHMT. Intriguingly. It has been 
published that mSHMT was found to be capable of partial complementation of the growth 
defects of c-Myc null cells, accounting on its role as a major source for the biosynthesis of 
nucleotide and amino acids(Nikiforov et al., 2002),  
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                     Methotrexate(MTX) is one of the most powerful anticancer agent, especially for 
human leukemia. Moreover, it considered to kill cells in the S- phase by means of binding to 
irreversibly to the enzyme DHFR(Yamauchi et al., 2005). In the present study We used MTX 
to synchronize cells in S- phase however, by serendipity we use high doses of MTX, which 
results in the accumulation in G0/G1 implying that either freezing or apoptosis. Nevertheless 
few cell thanks to folinic acid traverse the S- phase, indicating that folinic acid in optimal 
doses could reverse the effect of MTX.   
 
 
 
5- Conclusion and recommendations 
                Folinic acid is a powerful and indispensable drug. It is found to minimally reverse 
the adverse effects that triggered by UV irradiation, possibly by increasing the nucleotide pool. 
Importantly it  acts as a double-edged sword in treating cancer cells, as it behaves 
synergistically by abrogating and inhibiting  growth factor such as EGFR and IGF-1R. while 
in absence of growth factor it works differently as growth factor to cancer cells or by lowering 
the efficacy of anti- folate drug  especially when administered in hyper physiologic doses. 
Additionally, folinic acid could partially revert and restore the growth activity of c-Myc 
deprived cell this could crucially impact the potential new regimen for the treatment of tumour 
driven  by c-Myc.          
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